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ABSTRACT 
The proliferation of microarray experiments and the increasing 
availability of relevant amount of data in public repositories have created 
a need for meta-analysis methods to efficiently integrate and validate 
microarray results from independent but related studies. 
Despite its increasing popularity, meta-analysis of microarray data is 
not without problems. In fact, although it shares many features with 
traditional meta-analysis, most classical meta-analysis methods cannot be 
directly applied to microarray experiments because of their unique issues. 
Several meta-analysis techniques have been proposed in the context 
of microarrays. However, only recently a comprehensive framework to 
carry out microarray data meta-analysis has been proposed. Moreover 
very few software packages for microarray meta-analysis implementation 
exist and most of them either have unclear manuals or are not easy to 
apply. 
We applied four meta-analysis methods, the Stouffer’s method, the 
moderated effect size combination approach, the t-based hierarchical 
modeling and the rank product method, to a set of three microarray 
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studies on malignant pleural mesothelioma. We focused on differential 
expression analysis between normal and malignant mesothelioma pleural 
tissues. Both unfiltered and filtered data were analyzed. The lists of 
differentially expressed genes provided by each method for either kind of 
data were compared, also by pathway analysis. These comparisons 
highlighted a poor overlap between the lists of differentially expressed 
genes and the related pathways obtained using the unfiltered data. 
Conversely, a higher concordance of the results, both at the gene and the 
pathway level, was observed when filtered data were considered. The fact 
that a significant number of genes were identified by only one of the 
tested methods shows that the gene ranking is based on different 
perspectives. In fact, the analyzed methods are based on different 
assumptions and focus on diverse aspects in selecting significant genes. 
Since so far there is no consensus on what is (are) the ‘best’ meta-analysis 
method(s), it may be useful to select candidate genes for further analysis 
using a combination of different meta-analysis methods. In particular, 
differentially expressed genes detected by more than one method may be 
considered as the most reliable ones while genes identified by only a 
single method may be further explored to expand the knowledge of the 
biological phenomenon of interest. 
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1 INTRODUCTION 
Microarray technology simultaneously measures the mRNA of tens of 
thousands of genes in biological samples in a high-throughput and cost-
effective manner. Since its introduction in 1995 [1], microarray technology 
has improved dramatically and became a widely used tool to study the 
whole transcriptome of many organisms. It has been adopted to explore 
the molecular basis of fundamental biological processes and complex 
diseases [2, 3], to improve the disease taxonomy [4, 5], to classify patients 
into known disease subclasses [6], to analyze the response to drug 
administration [7], and to predict disease outcomes [8, 9]. 
Enhancements in microarray technology and its widespread use have 
led to the generation of a relevant amount of data and resulted in several 
large public data repositories such as Gene Expression Omnibus (GEO) [10] 
(http://www.ncbi.nlm.nih.gov/geo/) from NCBI, ArrayExpress [11] 
(http://www.ebi.ac.uk/arrayexpress/) from EBI and CIBEX (Center for 
Information Biology gene EXpression database) [12] 
(http://cibex.nig.ac.jp/).  
It is not uncommon to find multiple microarray gene expression 
studies performed by different research groups worldwide addressing the 
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same or similar biological questions. Hence there has been a growing 
interest in developing methods to efficiently integrate microarray data 
from independent studies with the aim of fully exploiting the rich 
information produced. Meta-analysis appears to be an effective solution 
to this pressing issue [13].  
As stated by Hedges, “meta-analysis consists of statistical methods 
for combining results from independent but related studies” [14]. 
However the term meta-analysis is also widely used in a broader sense, as 
we do here, to indicate the whole process of identification, selection, 
assessment and quantitative synthesis of several studies concerning a 
well-defined research question [15]. Many people use the term meta-
analysis interchangeably with systematic review, however not all the 
systematic reviews are meta-analyses. In fact a meta-analysis is a 
systematic review which provides a statistical synthesis of the results and 
produces an overall estimate of the effect of interest.  
Meta-analysis offers several practical advantages. 
First of all, meta-analysis represents an inexpensive solution to 
overcome the problem of reduced statistical power of microarray 
experiments and to reveal true effects of interest [16]. Typically, in 
microarray experiments many probes are investigated in few samples due 
to the high cost of this technology or the lack of biological replicates 
available. The straight consequence is that studies with small sample sizes 
are less likely to detect true effects and more prone to false positive and 
false negative results. Putting results together, therefore, increases the 
sample size and the statistical power of the study. It also allows a more 
accurate estimation of the effect, even if derived from small but 
consistent variations.  
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Moreover, meta-analysis has the potential to strengthen and extend 
the results obtained by individual studies and to increase their reliability. 
Indeed, it has been shown that microarray studies are poorly reproducible 
across platforms and/or laboratories [17, 18]. Technological differences 
among different microarray platforms [19], large variations in biological 
and experimental settings, small sample sizes and inappropriate statistical 
methods [20, 21] have been pointed out as the major sources that 
contribute to the inconsistency of microarray results. Many of these can 
be assessed and controlled or overcome by the use of standard reporting 
methods and the careful application of large-scale meta-analysis 
techniques with an appropriate statistical modeling of the inter-study 
variation [16].  
Meta-analysis has been widely used in the area of medical and 
epidemiological research as well as in the sociological and behavioral 
sciences [22]. The applicability of meta-analysis methods to microarray 
datasets was demonstrated for the first time in 2002 by Rhodes who 
combined four datasets on prostate cancer to determine genes that were 
differentially expressed between clinically localized prostate tumor and 
benign prostate tissue samples [23]. Since then, several applications of 
meta-analysis to microarray data appeared in the literature [24-26].  
Through a systematic search on PubMed, Tseng and colleagues [27] 
found that 333 microarray meta-analysis papers (including reviews, 
biological applications, methodological articles and database/software 
description papers) were published until December 2010, thus confirming 
the relevant interest of the scientific community in this challenging task. In 
more than half of the above mentioned publications, meta-analysis was 
applied to identify Differentially Expressed Genes (DEGs) between two or 
more conditions [28-30]. However microarray studies have also been 
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combined for classification analysis [31], to identify co-expressed genes or 
to build gene networks [32-34], to evaluate reproducibility and bias across 
studies [35-37]. Figure 1.1 illustrates a microarray meta-analyses summary 
performed by Tseng and colleagues [27]. 
 
Figure 1.1: Classification of the 333 microarray meta-analysis papers reviewed by 
Tseng based on the type of paper (A) and the purpose of meta-analysis (B) (image 
modified from [27]) 
 
Despite its increasing popularity, however, meta-analysis of 
microarray data is not without problems. In fact, although it shares many 
features with traditional meta-analysis, most classical meta-analysis 
methods cannot be directly applied to microarray experiments because of 
their unique issues such as the large number of variables involved and the 
technical complexities of combining data across different experimental 
platforms (e.g. gene nomenclatures, species and analytical methods) [38]. 
1.1 AIM OF THE STUDY 
In this study, we focused on the application of meta-analysis to the 
two-class comparison microarray experiments. The objective of this kind 
of studies is to identify DEGs between two well-defined conditions, 
namely cases and controls. Four statistical approaches were comparatively 
evaluated: the weighted version of the inverse normal method by Marot 
and Mayer [39] and the moderated effect size combination approach 
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proposed by Marot [40], both implemented in the R (http://www.r-
project.org/) package metaMA, the t-based hierarchical modeling 
described in Choi et al. [16] and implemented in the Bioconductor 
(http://www.bioconductor.org/) package GeneMeta [41] and the rank 
product method with the RankProd Bioconductor package [42]. These 
methods were applied to a set of three publicly available microarray 
studies on malignant pleural mesothelioma to identify DEGs between 
normal and malignant mesothelioma pleural tissues. Since it is not yet 
clear if filtering is beneficial from a meta-analysis perspective, both 
unfiltered and filtered data were analyzed to evaluate the impact of a 
common filtering strategy on meta-analysis results. 
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2 BACKGROUND 
A considerable literature has been published to guide the whole 
review process and the meta-analysis for medical and epidemiological 
studies [43-45]. Moreover, some guidelines for the reporting of systematic 
reviews and meta-analyses, outlined in the Quality of Reporting of Meta-
Analyses statement for randomized trials by QUORUM group [46] and its 
evolution into PRISMA (Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses) [47], are universally accepted. 
On the contrary, there is little guidance to carry out a meta-analysis 
of microarray datasets. The first attempt in this direction was represented 
by the paper of Ramasamy and colleagues who proposed a seven-step 
practical approach to conduct a meta-analysis of microarray datasets: “(1) 
Identify suitable microarray studies; (2) Extract the data from studies; (3) 
Prepare the individual datasets; (4) Annotate the individual datasets; (5) 
Resolve the many-to-many relationship between probes and genes; (6) 
Combine the study-specific estimates; (7) Analyze, present, and interpret 
results” [48]. Steps from 2 to 5 apply separately to the individual datasets. 
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Each step, in turn, consists of several critical points that will be highlighted 
and examined in detail in the following paragraphs. 
2.1 IDENTIFICATION OF SUITABLE MICROARRAY STUDIES 
A meta-analysis begins with a well-formulated objective. As 
highlighted in the introduction, meta-analysis of microarray studies can be 
used for several purposes, for example to identify DEGs between two or 
more groups, to identify co-expressed genes, to build gene networks or to 
evaluate reproducibility and bias across studies. In the following we will 
focus on meta-analysis for DEGs detection, however most of the 
considerations apply regardless of the specific topic. 
The study selection process is guided by the definition of the 
inclusion/exclusion criteria. These criteria should be a priori established 
and should derive immediately from the objective(s) of the study. They 
can be based on biological (e.g. specific disease, type of outcome, type of 
tissues, organism) or technical issues (e.g., density of array, minimum 
number of arrays). A clear, detailed and unambiguous formulation of 
inclusion/exclusion criteria, possibly in the form of a real protocol, is 
essential to avoid the most frequent criticism of the meta-analysis, that is 
“mixing apples and oranges” [49]. 
Locating the studies is by far the most difficult and the most 
frustrating aspect of any meta-analysis but it is the most important and 
critical step. Many meta-analyses begin with a systematic literature 
search. Keywords concerning the research question and their synonyms 
are typically used to identify studies for inclusion in the review. In order to 
retrieve all the relevant studies on a given topic, the search should be as 
comprehensive as possible, therefore it is recommended to search all the 
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main electronic databases of abstracts listed in Table 2.1. Reading the 
latest review articles and contacting specific investigators that are known 
to be active in the area can help to identify additional studies missed by 
automated search and ongoing research efforts with unpublished data. 
Database Web site 
Online repositories of abstracts   
PubMed http://www.pubmed.gov/  
Google Scholar http://scholar.google.com/  
Web of Science (requires subscription) http://wos.mimas.ac.uk/  
SCOPUS (requires subscription) http://www.scopus.com/  
Microarray repositories recommended by MIAME for mandatory data deposition 
Array Express http://www.ebi.ac.uk/arrayexpress/  
CIBEX http://cibex.nig.ac.jp/ 
Gene Expression Omnibus (GEO) http://www.ncbi.nlm.nih.gov/geo/  
Other useful sites for data identification   
ONCOMINE http://www.oncomine.org/  
Stanford Microarray Database (SMD) http://smd.stanford.edu/  
Table 2.1: Useful web resources to identify suitable studies for microarray meta-
analysis (modified from [48]) 
 
Concerning microarrays, it is appropriate to extend the search to 
public microarray data repositories, as well as to a few more specialized 
databases, listed in Table 2.1. A quick review of the abstracts and 
experiments description is essential to eliminate those studies that are 
clearly not relevant to the meta-analysis or do not meet the specified 
selection criteria.  
After the identification of candidate studies from abstracts, the 
articles or inherent information from authors, where available, have to be 
retrieved to confirm their eligibility. To limit the risk of compromising the 
quality of meta-analysis results, the included studies should undergo a 
quality assessment, that is an accurate evaluation of the study 
characteristics in terms of the study design, implementation and analysis 
[49]. In fact, if a meta-analysis includes many low-quality studies, then the 
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errors in the primary studies will be carried over to the meta-analysis, 
where they may be harder to identify, and the obtained result will be 
biased (“garbage in, garbage out“). Regarding microarray studies, the 
quality assessment should be performed at the study-level as well as at 
the data-level, as will be extensively described in the following 
paragraphs. 
2.2 EXTRACTION OF THE DATA FROM STUDIES 
As illustrated in Figure 2.1, there are four levels of data arising from 
microarray analysis: (1) the scanned images, (2) the raw data or FLEO 
(Feature-Level Extraction Output) files [48], such as Affymetrix CEL and 
GenePix GPR files, that is the quantitative outputs from the image analysis 
software, (3) the Gene Expression Data Matrix (GEDM) arising from the 
application to raw data of preprocessing algorithms, which represents the 
gene expression summary for every probe and sample and (4) the list of 
genes that are declared as differentially expressed in the study. 
 
Figure 2.1: Types of data relevant to a microarray experiment (image modified 
from [50]) 
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According to the conclusions of the study of Suarez-Farinas [51] and 
the recommendations of Ramasamy [48], raw data represent the ideal 
input for meta-analysis because they are independent of the specific 
preprocessing algorithms used and can be converted to GEDMs in a 
consistent manner thus producing more comparable data. By contrast, 
using GEDMs as input for meta-analysis is unsuitable because they 
considerably depend on the choice of the preprocessing algorithms, which 
may produce non-combinable results. The same considerations apply to 
the lists of DEGs. In fact, even if DEGs lists are easier to obtain since they 
are often included in the main text or supplementary data of published 
microarray studies, they heavily depend on the preprocessing algorithms, 
the statistical methods and cutoffs, and the annotation system adopted in 
the original study. 
In relation to the data retrieval phase there are three major 
problems: (1) the efficient access to microarray data, (2) their 
standardization, and (3) the comparability across platforms. 
2.2.1 MICROARRAY STANDARDS AND REPOSITORIES 
In the past years, most of the publicly available microarray data 
produced by different research groups worldwide were scattered in the 
web both as supplementary data of a published article and as links to the 
authors web pages. Consequently it was very difficult for the researchers 
to locate and systematically collect the relevant data available. This 
problem has been addressed and partially solved through the 
development of several public repositories. Today, many web databases 
exist. ArrayExpress  from EBI and GEO from NCBI are the two largest ones: 
on 24 January 2013, GEO contained 35618 experiments and 870318 
samples while 35035 experiments and 1009648 assays were available in 
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ArrayExpress. Several other microarray databases are housed in specific 
universities or groups, including Stanford Microarray Database (SMD) and 
RNA Abundance Database (RAD; http://www.cbil.upenn.edu/RAD [52]) 
from University of Pennsylvania, or are focused on particular organisms 
(e.g. yeast Microarray Global Viewer; http://www.trans 
criptome.ens.fr/ymgv/ [53]) or diseases (e.g. ONCOMINE and Cancer 
Genome Workbench (CGWB) [54]) [27, 55]. 
At the beginning the effectiveness and the use of these public 
databases were severely limited by two factors: (1) the incompleteness or 
the lack of experimental information needed to assess the quality of the 
data, to repeat a study or to reanalyze the data, and (2) the lack of 
standards for presenting and exchanging such data. A considerable 
improvement occurred with the publication of the Minimum Information 
About a Microarray Experiment (MIAME) [50] standard by the Microarray 
Gene Expression Data Society (MGED) (http://www.mged.org). MIAME 
guidelines describe the minimum information that has to be provided to 
enable the comprehension of the results of a microarray experiment and 
their validation by independent researchers. The information required by 
MIAME standard includes the experimental design, array design (e.g. 
platform type and provider, gene identifiers, probe oligonucleotides), 
details on samples and treatments applied (e.g. laboratory protocols for 
sample treatments, extraction and labeling), hybridization conditions, 
measurements and normalization controls (e.g., normalization techniques 
applied and control elements used to obtain the final processed data). The 
current MIAME standard requires the submission to public databases of 
both the FLEO and GEDM files [56]. 
Since the MIAME publication in 2001, the major data repositories are 
supporting the archiving of MIAME-compliant data, and most peer-review 
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journals have adopted MIAME guidelines as a requirement for the paper 
publication [57]. The availability of standardized microarray gene 
expression data in these public repositories: (1) greatly enhanced the 
accessibility, the retrieval and the sharing of the data; (2) increased the 
reliability of the data quality and (3) improved the comparability and 
integration of data from different laboratories in a meta-analysis 
perspective. 
Despite the wide adoption of MIAME standard by public microarray 
repositories and scientific journals, only about one-third of published 
studies have their raw data deposited in public databases [58]. Moreover, 
even when data are available, the incomplete annotation and/or the lack 
of data processing and analysis description limit their usefulness for 
further analyses [59]. 
2.2.2 CROSS-PLATFORM COMPARABILITY 
One major issue in meta-analysis of microarray datasets concerns the 
possibility of combining raw measurements from different microarray 
technologies.  
Although all DNA microarrays are based on the hybridization of 
complementary nucleic acid strands, the available platforms differ in the 
manufacturing process, hybridization protocols, image and data analysis, 
making comparison of the data across platforms very difficult. 
Based on the length of the probes, microarrays can be classified as: 
(a) cDNA arrays, using probes constructed with PCR products of up to a 
few thousands base pairs, (b) short oligonucleotide arrays, using short 
probes (25-30 mer), such as Affymetrix GeneChip® arrays (Santa Clara, CA, 
USA), and (c) long oligonucleotide arrays, such as those produced by 
Agilent® (Palo Alto, CA, USA), using 60-70 mer long probes. Probe design 
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varies among microarrays. Long oligonucleotides are thought to mimic the 
properties of cDNA probes offering high sensitivity and good specificity, 
while giving better probe homogeneity. For both cDNA and long 
oligonucleotide arrays, typically one probe is designed for each gene that 
is to be probed [60]. In Affymetrix arrays, for each gene, a unique region is 
identified, then a set of 11–20 complementary probes spanning this region 
is synthesized. These complementary probes are referred to as ‘Perfect 
Match’ probes (PM). Each PM probe is then paired with a ‘Mismatch’ 
probe (MM), which has the same sequence as the PM except the central 
base replaced with a mismatched nucleotide. The complete set of PM and 
MM probe pairs for each gene is referred to as a ‘probe set’ [61]. 
Short oligonucleotides showed a higher specificity in target 
identification compared to long cDNA clones that were more prone to 
cross-hybridization [62]. 
Gene annotation can also contribute to platform differences. Gene 
expression values can be compared effectively across platforms only if 
genes are accurately identified on all platforms. Unfortunately, the lack of 
standardized annotation methods and of a regular update of annotations 
severely affect the cross-platform comparability. Moreover, the presence 
of poorly annotated and/or not specific probes on some arrays contribute 
to increase misalignments among platforms [63]. In any case, even if an 
accurate translation between different nomenclatures is achieved, the 
differences in how different platforms measure specific transcripts still 
remain and could have important impact on any attempt to conduct 
effective microarray data meta-analysis by increasing the false negative 
rate [38]. 
Based on the expression measurement techniques, microarray 
technologies can be classified as: one-color or single-channel and two-
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color or two-channel. In one-color microarrays, such as Affymetrix arrays, 
a single labeled RNA sample is hybridized on a chip thus providing an 
absolute measurement of expression in the given sample (absolute 
quantification). By contrast, expression levels measured by cDNA 
microarrays and long oligonucleotide platforms, using two-channel 
detection, are usually reported as a ratio of the signal from a target RNA 
sample relative to one from a co-hybridized sample (relative 
quantification) [1]. These different measurement strategies result in 
diverse experimental designs which complicate the direct comparison and 
integration of the data. The use of a common reference design for the 
two-channel platforms, where each experimental RNA sample is co-
hybridized with a reference RNA sample, represents a valid solution as it 
closely reproduces the single-channel approach. 
Finally, different preprocessing steps, such as quality filtering, 
background correction and normalization, adopted to transform the raw 
data into the corresponding gene expression values, have substantial 
influence on the data [64]. 
All these differences produce qualitatively different data whose 
comparability has been widely debated. See for references [19, 65-71]. 
2.3 PREPARATION OF THE INDIVIDUAL DATASETS 
Once the raw data from individual studies have been collected, they 
have to be converted into GEDMs, which can then be used as input for the 
meta-analysis. 
Before the preprocessing or transformation steps, Ramasamy [48] 
suggests to check the quality of the arrays in the individual studies to 
identify and remove those of poor quality. Microarray quality is assessed 
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by comparing suitable numerical summaries (e.g. average background, 
scale factors, percentage of present calls,) across microarrays, so that 
outliers and trends can be visualized and poor-quality arrays can be 
identified. There are many Bioconductor packages for quality assessment 
including arrayMagic [72] for the two-color technology platform, 
Simpleaffy [73] and affyPLM [74] for the Affymetrix platform and 
ArrayQualityMetrics [75] which manages many microarray technologies. 
Only the arrays that pass the quality check should be included in the meta-
analysis. 
At this point the data undergo different levels of transformation or 
preprocessing that are: background or mismatch subtraction, probe set 
summarization which combines multiple measures of the same transcript, 
normalization within and between arrays. As it is now widely known [76], 
using different raw data transformation methods leads to disagreements 
in the resulting DEGs even within one experiment on a single platform.  
It is thus evident the need to consistently process the data to remove 
any systematic differences. The simplest case is when data from multiple 
studies  the same platform have to be combined. In this case it is, in fact, 
sufficient to apply the same algorithm to all datasets. Much more often, 
however, researchers are faced with the problem of combining datasets 
from different platforms, which may have different designs and thus 
different preprocessing methods options. In this case, comparable 
preprocessing algorithms should be applied to the individual datasets. 
There are very few universally applicable preprocessing algorithms, such 
as the variance stabilizing normalization [77]. By contrast, it is more 
common to use different preprocessing methods for each platform. 
Unfortunately, there is currently no consensus on which preprocessing 
algorithms produce comparable expression measurements across 
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different platforms [48]. However, it has been found that while the default 
procedures suggested by microarray manufacturers result in general 
slightly better accuracy, the results provided by alternative approaches, 
like those proposed by Bioconductor packages, are far more precise [70]. 
The identification and adjustment of any batch effects, especially in 
large microarray datasets, are also of great importance. Many different 
experimental features can cause biases including different sources of RNA, 
different microarrays print batches or platforms, as shown in Figure 2.2. 
Unsupervised visualization techniques such as Support Vector Machines 
(SVM) [78], Singular Value Decomposition (SVD) [79], Principal Component 
Analysis (PCA) [80] and the Distance Weighted Discrimination (DWD) 
method proposed by Benito and colleagues [81] can help to identify any 
grouping caused by experimental factors within microarray datasets.  
 
Figure 2.2: A visualization of batch effect sources at each stage of a microarray 
gene expression experiment (image from [82]) 
 
In single-study analysis it is common practice to filter out probes 
based on different criteria. Probes showing severe manufacturing or 
hybridization problems or a signal-to-noise ratio below a fixed threshold, 
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probes marked as ‘absent’ or showing little variation among experimental 
conditions are usually excluded or under-weighted from the successive 
analysis. To date, it has been demonstrated that filtering improves cross-
platform reproducibility [21, 64, 67, 83] but it is not yet clear whether 
filtering is beneficial to meta-analysis. 
Another problem that may occur in this phase deals with the 
management of possible within studies technical replicates. In fact, 
technical replicates cannot be considered as independent observations 
and should be aggregated taking, for example, the mean or median of the 
corresponding gene expression measurements. 
Finally, one could check that the processed expression values from 
multiple platforms are comparable. Concerning this topic, one may use 
visualization techniques such as multidimensional scaling [84] to 
investigate for any clustering of arrays by studies. 
2.4 ANNOTATION OF THE INDIVIDUAL DATASETS 
The first step to combine different microarrays datasets is to find 
genes common to all arrays. The annotation of the individual datasets is a 
non trivial task because of the lack of a uniform nomenclature system and 
the many-to-many relationship between probes and genes. 
Microarray manufacturers use specific probe-level identifiers (probe 
IDs) (e.g. Affymetrix probe ID) to identify the probes present on their own 
arrays. Moreover, different manufacturing techniques lead to the creation 
of multiple probes for the same gene. Therefore, one needs to identify 
which probes represent a given gene within and across platforms. In fact, 
even if the datasets share the same platform, the combination of different 
array versions creates serious difficulties, since the probe IDs are not 
 
20 
conserved from version to version. In conclusion, to combine microarray 
datasets across studies a unique nomenclature must be adopted and all 
the different platform-specific IDs must be translated to a common 
identifier. There are many different options that could be used to this end. 
Genbank or RefSeq [63] accession number, Unigene ID [85] and Entrez ID 
[86] are the most common. Accession numbers are associated with 
specific transcripts, then there may be multiple per gene. Mapping 
between platforms on the basis of the accession number could produce an 
accurate result, as one can be confident that the probes are truly 
measuring the same entity; however, such an approach would be 
problematic as there would be many accession numbers for which probes 
only exist on one platform, greatly diminishing the ability to map between 
platforms. For this reason, mapping on the gene level is the most common 
choice. This allows to incorporate the information from many more 
probes, as it is much more likely to be able to find some probes associated 
with a gene for each platform than to find a probe associated with a 
specific accession number. Unigene and Entrez Gene have different 
strengths and weaknesses. While Unigene IDs may incorporate more 
information, it is very dynamic and is constantly being revised. Entrez IDs, 
on the other hand, are very stable and have been well-curated [87]. 
The problem of matching platform-specific probe IDs can be tackled 
in three ways. The traditional method is to use the annotation files 
provided by the manufacturers. The accuracy of these files was long 
criticized as the knowledge of the transcriptome is constantly growing. 
However, in recent years more and more manufacturers provide to 
release updated annotation files with varying degrees of regularity in an 
attempt to keep these annotations current.  
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Another option is to align the probe sequences provided by the 
vendors to a recent revision of either the Genome or the Transcriptome 
using the BLAST algorithm [88], trying to obtain more up-to-date gene-to-
probe associations. It has been shown that cross-platform correlations 
improved using stringent sequence matching of the probes on the 
different platforms [89]. However, the probe sequences are not always 
available and this procedure can be computationally intensive and time-
consuming for very large numbers of probes. 
Alternatively, one can simply map probe IDs to a gene-level identifier 
(gene ID) such as Entrez ID or UniGene ID. Many published microarray 
meta-analyses [24, 26, 51, 90] have relied on UniGene ID to unify the 
different datasets, across platforms and array versions. The translation of 
the probe IDs to the corresponding gene IDs can be performed using 
either some Bioconductor annotation packages (e.g. annotate [Gentleman 
R. annotate: Annotation for microarrays. R package version 1.36.0.], 
annotationTools [91]) that aggregate the information from various 
platform-specific Bioconductor packages, or Web tools such as SOURCE 
[92] and RESOURCERER [93], MADGene [94], DAVID converter [95] and 
Onto-Translate [96]. The same mapping build, ideally the most recent, 
should be used for all datasets to avoid inconsistencies between releases 
[48]. 
Allen and colleagues [87] found that a BLAST alignment of the probes 
to the Transcriptome was more accurate than using the vendor’s 
annotation or Bioconductor packages. They also proposed a combination 
of all three methods (the “Consensus Annotation”) showing that it yielded 
the most consistent expression measurements across platforms. 
The annotation of individual datasets is further complicated by the 
non univocal relationship between probes and genes, which means that in 
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some cases a probe could report to more than one gene and vice versa. 
Many probes can map to the same gene ID because of the clustering 
nature of the UniGene, RefSeq, and BLAST systems involved, or because 
the microarrays used contain duplicated probes. Vice versa, a probe may 
map to more than one gene ID if the probe sequence is not specific 
enough. Sometimes, a probe has insufficient information to be mapped to 
any gene ID. These probes should be removed from further analysis. 
The simplest and even most stringent approach to solve these 
confounding situations is to use only the probes with one-to-one mapping 
for further analysis, thus excluding probes without a gene ID, probes 
mapping to multiple gene IDs and probes mapping to the same gene ID. 
Alternatively, probes with multiple gene IDs may be considered as 
independent gene expression measurements and be replaced by a new 
record for each gene, while multiple probes mapping to the same gene ID 
can be summarized using one of the following options: (1) selecting a 
probe at random, (2) taking the average of expression values across 
multiple probe IDs to represent the corresponding gene, (3) choosing the 
probe ID with the largest Inter Quartile Range (IQR) (or other similar 
statistics, such as standard deviation or coefficient of variation) of 
expression values among all multiple probe IDs to represent the gene. 
Although the option number 2 has been widely used due to its simplicity, 
IQR method is biologically more reasonable and robust and is highly 
recommended [97].  
Recently, the MicroArray Quality Control (MAQC) project proposed 
another alternative. A single RefSeq ID was selected for each probe 
mapping to multiple RefSeq IDs, primarily the one annotated by TaqMan 
assays, or secondarily the one present in the majority of platforms. When 
a platform contained multiple probes matching the same RefSeq entry, 
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only the probe closest to the 3’ end of the RNA sequence was included 
[71]. 
The multiple gene expression datasets may not be very well aligned 
by genes and the number of genes in each study may be different. 
Therefore the common genes across multiple studies have to be identified 
and extracted. When a large number of studies were included in the meta-
analysis, the number of genes common to all studies may be very small. At 
this point there are two possibilities: using only genes appearing in all 
datasets, or including also genes appearing in at least a pre-specified 
number of studies.  
Having solved the many-to-many relationship by expanding and 
summarizing probes, one summary statistic per gene ID per study is 
available. The next step will be to combine the summary statistic for each 
gene ID across the studies using a meta-analysis technique. 
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3 STATISTICAL METHODS FOR  
MICROARRAY DATA META-ANALYSIS  
This chapter deals with the sixth step of Ramasamy’s guidelines for 
microarray meta-analysis. The choice of a meta-analysis method depends 
on the type of outcome (e.g. binary, continuous, survival), the objective of 
the study and the type of available data. As previously illustrated, we 
focused on the two-class comparison, the most commonly encountered 
application of meta-analysis to microarray data, whose aim is the 
detection of DEGs between two experimental groups or conditions.  
There are two principal approaches to perform a meta-analysis, the 
relative and the absolute approach [98]. The relative meta-analysis is the 
most common one and is based on the calculation of a relative score 
expressing how each gene correlates to the experimental condition or 
phenotype of interest in each dataset. These scores are used to quantify 
the differences or similarities among studies and are integrated to find 
overall results (see Figure 3.1). 
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Figure 3.1: Stages of relative meta-analysis of microarray data (image from [13]) 
 
In contrast, in the absolute meta-analysis raw data from various 
microarray studies are integrated after transforming the expression values 
to numerically comparable measures. The derived data from the individual 
studies are normalized across studies and subsequently merged, thus 
enlarging the sample size and increasing the power of statistical tests. 
Traditional microarray data analysis is then carried out on the new merged 
dataset (see Figure 3.2) [13, 99].  
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Figure 3.2: Stages of absolute meta-analysis of microarray data (image from [13]) 
 
Although merging data can be attractive for its intuitiveness and 
convenience, cautions have to be taken since normalizations do not 
guarantee to remove all cross-study differences. There are few examples 
of studies where the absolute meta-analysis has been applied [31, 100, 
101]. Contrary to relative meta-analysis, which is always possible for cross 
lab, platform and even species comparisons, absolute meta-analysis 
usually considers studies from the same or similar array platform [102, 
103]. The collection of datasets from only one platform allows to pre-
process and normalize data using the same method on all samples 
simultaneously. 
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In recent years several relative meta-analysis methods have been 
proposed using different approaches. There are four generic ways of 
combining information for DEGs detection:  
1. Vote counting 
2. Combine p-values 
3. Combine effect sizes 
4. Combine ranks. 
They differ in the type of statistics measures proposed to summarize 
the study results. 
3.1 VOTE COUNTING 
Vote-counting is the simplest of the above approaches. For each 
gene, vote counting simply counts the number of studies in which a gene 
has been claimed significant [104]. To provide a statistical basis to vote 
counting techniques results, one can either calculate the significance of 
the overlaps using the normal approximation to binomial as described in 
Smid and colleagues [105] or calculate the null distribution of votes using 
random permutations [24]. For very small numbers of studies (usually 2–
4), the results can be summarized using a Venn diagram which displays the 
intersection and union distribution of DEGs lists detected by each 
individual study. In literature, it is well known that vote counting is 
statistically inefficient [14]. Moreover, vote counting does not yield an 
estimate of differential expression extent and the results highly depend on 
the statistical methods used in individual analyses. On the other hand, 
vote counting is useful when raw data and/or p-values for all genes are 
not accessible while only the lists of DEGs are available for each study. 
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Vote counting in the context of microarrays has been used 
successfully by Rhodes and colleagues [24], who applied it to identify a 
shared gene expression signature across cancer subtypes. First t-tests 
were calculated by comparing the treatment and control group in each 
study. Then, a binary score was assigned to each gene in each study based 
on whether its p-value passed a threshold (vote = 1) or not (vote = 0). 
Finally, a simulation of the likelihood of obtaining k or fewer votes (where 
k is the number of studies included) was done to estimate a significance 
level. 
3.2 COMBINING P-VALUES 
Combining p-values from multiple studies for information integration 
has long history in statistical science. Methods based on the combination 
of p-values are easy to use and provide more precise estimates of 
significance. However these methods do not indicate the direction (e.g. up 
or down regulation) nor the extent of differential expression. Moreover 
the results highly depend on the statistical methods used in individual 
analyses. Nevertheless, integration of p-values does not require that 
different studies use the same measurement scales therefore it is possible 
to combine results from studies realized by completely different 
technologies. 
Several methods exist for combining p-values from independent 
tests; below, four p-value combination methods used in the context of 
microarray meta-analysis are briefly described. 
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3.2.1 FISHER’S METHOD 
Fisher’s method [106] computes a combined statistics from the log-
transformed p-values obtained from the analysis of the individual 
datasets:  
(1)         (∏    
 
   ) 
where pgi is the unadjusted p-value from one-sided hypothesis testing for 
gene g and study i and k being the number of individual combined studies.  
The meta-analysis null hypothesis is that all the separate null 
hypotheses, are true, whereas the alternative hypothesis is that at least 
one of the separate alternative hypotheses is true. Assuming 
independence among studies and p-values calculated from correct null 
distributions in each study, Sg follows a chi-square distribution with 2k 
degrees of freedom under the joint null hypothesis of no differential 
expression, thus p-values of the combined statistics can be calculated for 
each Sg. Alternatively, statistical inference can be done non-parametrically 
using a permutation approach. As there are many genes, p-values of the 
summary statistics must be corrected for multiple testing using one of the 
available procedures such as the Bonferroni correction, the false discovery 
rate (FDR) proposed by Benjamini and Hochberg [107] or its modified 
version proposed by Storey [108]. Finally, a threshold is chosen and two 
meta-lists, that are the lists of DEGs resulting from the meta-analysis, of 
over and under-expressed genes are reported. It is worth pointing out that 
Fisher’s product should be applied to p-values for up and down regulation 
separately. Using p-values from two-sided testing means ignoring the 
direction of the significance and may lead one to select genes that are 
discordant in direction of gene regulation between the studies [109]. 
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Rhodes and colleagues [23] were the first who applied Fisher’s method to 
microarray data. They identified a meta-signature of prostate cancer 
combining the results of four studies performed on different platforms. 
Some variations to Fisher’s method have been proposed that give 
different weights to p-values from each dataset. Weight assignment can 
depend on the reliability of each p-value based on the data quality. 
Recently, Li and Tseng [110] introduced an adaptively weighted Fisher’s 
method (AW) where the weights are calculated according to whether or 
not a study contributes to the statistical significance of a gene. Li and 
Tseng showed the superior performance, in terms of power, of their AW 
statistics compared to Fisher’s equally weighted and other p-values 
combination methods, like Tippett’s minimum p-value [111] and Pearson’s 
(PR) statistics. 
3.2.2 STOUFFER’S METHOD 
Instead of log-transformation, Stouffer’s method [112] uses the 
inverse normal transformation. Unlike the Fisher’s method, which requires 
to treat over and under-expressed genes separately, the inverse normal 
method is symmetric in the sense that p-values near zero are accumulated 
in the same way as p-values near one [14]. In the Stouffer’s method, the 
one-sided p-values for each gene g from k individual studies are 
transformed into z scores and then combined using the following 
expression: 
(2)     ∑  
         
 
   √ ⁄  
where φ-1( ) is the inverse cumulative distribution function of 
standard normal distribution. Under the null hypothesis, the z statistic 
follows a normal N(0,1) distribution and therefore a p-value for each Zg 
 
31 
can be calculated from the theoretical normal distribution. Finally, to take 
into account multiple comparisons, the FDR or other multiple testing 
correction methods can be applied. An alternative to (2) is to use the 
weighted method proposed by Marot and Mayer [39] which is 
implemented in the R package metaMA. Here: 
(3)     ∑    
         
 
   √ ⁄  
and  
(4)    √   ∑    
 
   ⁄  
being ni the sample size of study i. 
3.2.3 MINP AND MAXP METHODS 
In the minP [111] and maxP [113] methods, for each gene, the 
minimum or maximum p-values over different datasets are taken as the 
test statistics. Smaller minP or maxP statistics reflects stronger differential 
expression evidence, however while minP declares a gene as differentially 
expressed if it is in any of the studies, maxP tends to be more conservative 
considering as differentially expressed only genes that have small p-values 
in all studies combined.  
Combining p-values are techniques that in theory could use the 
published lists of DEGs, but may not be able to do so in practice. For 
example, most publications report the significant genes based on two-
sided p-values, while the aforementioned methods require one-sided p-
values. So it is preferable to use the raw data to minimize the influence of 
different methods across datasets. 
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3.3 COMBINING EFFECT SIZES 
Methods based on the combination of effect sizes have been the 
most common approach to the meta-analysis of microarray studies. In 
statistics, an effect size is a measure of the strength of a phenomenon 
[114] (e.g. the relationship between two variables in a statistical 
population) or a sample-based estimate of that quantity. In general, effect 
sizes can be measured in two ways: 
1. as the standardized difference between two means, or 
2. as the correlation between the two variables [115].  
Standardized Mean Difference (SMD) is the difference between two 
means, divided by the variability of the measures. Effect sizes based on 
SMD include Cohen’s d [116], Hedges’ g [14], and Glass’s delta. All three 
employ the same numerator (i.e. the difference between group means) 
but different estimates of the variability at the denominator [117].  
An effect size approach is effective for microarray data application. 
First it provides a standardized index. At present, the measure of 
expression levels is not interchangeable in particular between 
oligonucleotide arrays and cDNA arrays. cDNA microarrays report only the 
relative change compared to a reference, which is rarely standardized. 
Obtaining effect sizes facilitates the combining of signals from one-color 
and expression ratios from two-color technology platforms. Second, it is 
based on a well-established statistical framework for the combination of  
different results. Third, it is superior to other meta-analytic methods in 
that it has the ability to manage the variability between studies. 
Moreover, in comparison to the p-values summary approaches, combining 
effect sizes gives information about the magnitude and direction of the 
effect. 
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In meta-analysis, the basic principle is to calculate the effect sizes in 
individual studies, convert them to a common metric, and then combine 
them to obtain an average effect size. Once the mean effect size has been 
calculated it can be expressed in terms of standard normal deviates (Z 
score) by dividing the mean difference by its standard error. A significance 
p-value of obtaining the Z score of such magnitude by chance can them be 
computed. 
Without loss of generality, we can assume that we are comparing 
two groups of samples, such as treatment (t) and control (c) groups, in 
each study i=1,2,..k. For each study i, let     and     denote the number of 
samples in treatment and control group, respectively, with           . 
Let       and       represent the raw expression values for gene g in 
conditions t and c for study i and replicate r and       and       be the 
corresponding log-transformed values. The data are assumed to be 
normally distributed as                 
   and        (        
 )  In a 
microarray experiment with two groups, the effect size refers to the 
magnitude of difference between the two groups’ means. There are many 
ways to measure effect size for gene g in any individual study [118]. The 
SMD proposed by Cohen is defined as: 
(5)     ( ̅        )    
    
⁄  
where  ̅    and      are the sample means of logged expression 
values for gene g in treatment (t) and control (c) group, in the ith study, 
respectively and    
    
 is the pooled standard deviation: 
(6)    
    
 √
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where     
  and     
  denote the sample variances of gene g's 
expression level in the treatment and control groups, respectively. 
Alternatively the SMD proposed by Hedges and Olkin [14] may be 
used. Hedges and Olkin showed that the classical Hedges'g overestimates 
the effect size for studies with small sample sizes. They proposed a small 
correction factor to calculate an unbiased estimate of the effect size which 
is known as the Hedges’ adjusted g and is given by: 
(7)    
     (  
 
         
) 
The estimated variance    
  of the unbiased effect size is given by: 
(8)    
  (   
      
  )     
 (          )
  
 
Then the effect size index     (or its unbiased version) across studies 
is modeled by a hierarchical model: 
(9) {
                            
  
                           
  
 
where    is the average measure of differential expression across 
datasets for each gene g, which is typically the parameter of interest,   
   is 
the between-study variance, which represents the variability between 
studies, and    
  is within-study variance, which represents the sampling 
error conditioned on the ith study. The model has two forms: a fixed 
effect model (FEM) and a random effect model (REM), and the choice 
depends on whether between-study variation is ignorable. A FEM assumes 
that there is one true effect    common to all studies included in a meta-
analysis and that all differences in observed effect sizes are due to 
sampling error alone. Thus   
   = 0 and consequently     ∼ N(  ,    
 ). By 
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contrast, in REM each study further contains a random effect that can 
incorporate unknown cross-study heterogeneity in the model. Thus     ∼ 
N(    ,    
 ) and      ∼ N(  ,   
 ). 
To determine whether FEM or REM is most appropriate, the 
Cochran’s Q statistic [119] may be used to test homogeneity of study 
effect, which is assessing the hypothesis that   
  is zero. Q statistic is 
defined as: 
(10)    ∑            ̂ 
        
where       
    is the statistical weight and 
(11)   ̂ 
  
∑       
 
   
∑    
 
   
 
is the weighted least squares estimator of the average effect size 
under the FEM which ignore the between-study variance. Under the null 
hypothesis of homogeneity (i.e.   
  = 0), Q follows a chi-square distribution 
with k-1 degree of freedom. A large observed value of the Q statistics 
relative to this distribution suggests the rejection of the hypothesis of 
homogeneity, which should indicate the appropriateness of the REM. It 
must be noted that this homogeneity test has low power [120] and non-
significant results do not imply that true homogeneity exists. If the null 
hypothesis of   
  = 0 is rejected, one method for estimating   
  is the 
method of moments developed by DerSimonian and Laird [121]: 
(12)  ̂ 
     {  
        
∑      ∑    
  
   ∑    
 
   ⁄  
 
   
} 
Then   
  is used to estimate the parameter    and its variance by a 
point estimator defined as in the generalized least squares method: 
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(13)  ̂ 
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and  
(14)    ( ̂ 
    
  )  
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where   
      
   ̂ 
     is the statistical weight under REM. 
The z statistic to test for DEGs under REM is then constructed as 
follows: 
(15)     ̂ 
 
   
  √   ( ̂ 
 
     )⁄  
The z statistic for FEM is the same as that for REM except that   
  = 0. 
To evaluate the statistical significance of the combined results, the p-
values can be obtained from a standard normal distribution N(0,1) using 
these Z scores. For a two-tailed test, the p-value for each gene is given by: 
(16)     (         ) 
where      is the standard normal cumulative distribution. To 
assess the statistical significance not assuming normal distribution, 
empirical distributions may be generated by random permutations. In 
both cases, the p-values obtained are unadjusted values which should be 
corrected to take into account the multiple comparisons. 
Choi and colleagues [16] were among the first who applied these 
models to microarray meta-analysis. To estimate the effect size they 
considered the unbiased estimator of the SMD defined in equation (7) 
where     was obtained from the standard t statistics for each gene from 
each individual dataset via the relationship:  
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(17)        √  ̃⁄  
with   ̃                     ⁄ . 
To estimate the statistical significance simultaneously addressing the 
multiple testing problem, Choi and colleagues adapted the core algorithm 
of Significance Analysis of Microarrays by Tusher and colleagues [122]. 
Column-wise permutations were performed within each dataset to create 
randomized data and z scores under the null distribution,   
   for 
permutation b = 1, 2, …B. The ordered statistics      (            ) and 
    
   (    
         
  ) were obtained and the FDR was estimated for a 
given gene by: 
(18)      
   ⁄  ∑ ∑  (     
      )    
∑  (         )   
 
where I(·) is the indicator function equal to 1 if the condition in 
parentheses is true, and 0 otherwise. The denominator represents the 
number of genes called significant in real data. The numerator is the 
expected number of falsely significant genes and given by the mean 
number across B permuted data. Integration of data using this meta-
analysis method facilitated the discovery of small but consistent 
expression changes and increased the sensitivity and reliability of analysis. 
Later, Hong and Breitling [109] found that this t-based meta-analysis 
method greatly improved over the individual analysis, however it suffered 
from potentially large amount of false positives when p-values served as 
threshold.  
The approach of Choi and colleagues has been implemented in the 
Bioconductor package GeneMeta [Lusa L, Gentleman R and Ruschhaupt 
M, GeneMeta: MetaAnalysis for High Throughput Experiments. R package 
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version 1.30.1] where both alternatives to evaluate the statistical 
significance of the combined results are available. 
Different variations of effect size models have also been developed 
by other research groups. Hu and colleagues [123] presented a measure to 
quantify data quality for each gene in each study where the quality index 
measured the performance of each probe set in detecting its intended 
target. As they used Affymetrix microarrays they exploited the detection 
p-values provided by Affymetrix MAS 5.0 algorithm [Affymetrix Microarray 
Suite User's Guide Version 5.0 Affymetrix, Santa Clara, CA; 2001] to define 
a measure of quality for each gene in each study and incorporated these 
quality scores as weights into a classical random-effects meta-analysis 
model. They demonstrated that the proposed quality-weighted strategy 
produced more meaningful results then the unweighted analysis. In a later 
paper, Hu and colleagues [124] proposed a re-parameterization of the 
traditional mean difference based effect size by using the log ratio of 
means, that is, the log fold-change, as an effect size measure for each 
gene in each study. They replaced the effect size defined in equation (5) 
with the following expression: 
(19)       ( ̅    ̅   ⁄ ) 
where  ̅    and  ̅    are the sample means of the unlog-transformed 
gene expression values for gene g in treatment and control group in a 
given study. The estimated variance    
  of this new effect size can be 
estimated as follows: 
(20)    
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Redefined     and    
  were then placed into the classical hierarchical 
model (9) using both the quality-weighted and quality-unweighted 
frameworks. Hu and colleagues’ idea comes from two well-known 
evidences. On the one hand the fact that, with small sample sizes, the 
traditional standard mean difference estimates are prone to unpredictable 
changes, since gene-specific variability can easily be underestimated 
resulting in large statistics values. Many efforts have been made to 
overcome this problem by estimating a penalty parameter for smoothing 
the estimates using information from all genes rather than relying solely 
on the estimates from an individual gene [122]. On the other hand the 
evidence that DEGs may be best identified using fold-change measures 
rather than t-like statistics [125]. Hu and colleagues applied their method 
to simulated datasets and real datasets focusing on the identification of 
differentially expressed biomarkers and their ability to predict cancer 
outcome. Their results showed that the proposed effect size measure had 
better power to identify DEGs and that the detected genes had better 
performance in predicting cancer outcomes than the commonly used 
standardized mean difference.  
Stevens and Doerge [126] proposed an alternative for the SMD as 
estimator for differential expression specific for Affymetrix data. It is 
represented by the signal log ratio (SLR) automatically reported by MAS 
5.0 [Affymetrix Microarray Suite User's Guide Version 5.0 Affymetrix, 
Santa Clara, CA; 2001], defined as the signed log2 of the signed fold-
chance (FC), that is, FC=2SLR if SLR≥0 and FC=(-1)2-SLR if SLR<0. The meta-
analytic framework is described in Choi and colleagues [16]. 
Unlike previously mentioned meta-analysis studies where the p-
values or effect sizes to be combined were based on standard t-tests, 
Marot and colleagues [40] proposed to extend these effect sizes to 
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account for moderated t-tests. In the last few years, several authors such 
as Smyth [127] or Jaffrézic and colleagues [128] showed that, in single 
study analyses, shrinkage approaches leading to moderated t-tests were 
more powerful to detect DEGs than gene-by-gene methods when small 
numbers of biological replicates are available. Indeed, shrinkage consists 
in estimating each individual gene value borrowing information from all 
the genes involved in the experiment. By decreasing the total number of 
parameters to estimate, the sensitivity is increased. Marot and colleagues 
considered two popular shrinkage approaches: that proposed by Smyth 
[127] and implemented in the Bioconductor package limma and that 
developed by Jaffrézic and colleagues [128] implemented in the R package 
SMVar. In the first approach, as the same variance is assumed for both 
experimental conditions in limma, the moderated effect size    
           
 
for a given gene in a given study can be estimated as in (17) where     is 
the limma moderated t-statistics. SMVar assumes different variances for 
treatment and control groups thus the moderated effect size for a given 
gene in a given study can be estimated as in(17) where     is Welch t-
statistics [129] and   ̃         . Moreover, the degrees of freedom 
gained using shrinkage approaches allowed Marot and colleagues to 
calculate the exact form of the variance for moderated effect sizes instead 
of the asymptotic estimator used by Choi and colleagues (see Equation 
(8)). Using the distribution of effect sizes provided by Hedges [130], it can 
be shown that: 
(21)             
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(22)        (
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where   ̃                    ⁄  in limma and   ̃          in 
SMVar and m is the number of degrees of freedom. In limma, m equals to 
the sum of prior degrees of freedom and residual degrees of freedom for 
the linear model of gene g. In SMVar, degrees of freedom are calculated 
by Satterthwaite’s approach [131]. Then the unbiased estimators can be 
obtained from the moderated effect sizes as: 
(23)    
            
         
           
 
This equation can be seen as an extension of Equation (7) with 
                ⁄  and        . Assuming that 
   (     )   , which holds exactly for standard effect sizes and works 
quite well in practice for moderated effect sizes, the variance of the 
unbiased effect sizes is computed as          
 . Since c(m)<1, unbiased 
estimators have a smaller variance than biased ones. The Marot and 
colleagues’ approach has been implemented in the R package metaMA 
which offers three variants of effect sizes (classical and moderated t-test) 
and uses explicitly the random effect model. Only the Benjamini and 
Hochberg [107] multiple testing correction is available. 
Recently, Bayesian meta-analysis models have also been developed. 
Choi and colleagues [16] introduced the first Bayesian meta-analysis 
model for microarray data which integrated standardized gene effects in 
individual studies into an overall mean effect. Inter-study variability was 
included as a parameter in the model with an associated uninformative 
inverse gamma prior distribution. Markov Chain Monte Carlo simulation 
was used to estimate the underlying effect size. Conlon and colleagues 
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[132] introduced two Bayesian meta-analysis models for microarray data: 
the standardized expression integration model and the probability 
integration model. The first model is similar in approach to that described 
in Choi and colleagues' study [16], except that standardized gene 
expression values (i.e. log-expression ratios standardized so that each 
array within a study has zero mean and unit standard deviation) were 
combined instead of effect sizes since the analyzed data are assumed to 
be from the same platform and comparable across studies. Conversely, 
the second model combines the probabilities of differential expression 
calculated for each gene in each study. Both models produce the gene-
specific posterior probability of differential expression, which is the basis 
for inference. Since the standardized expression integration model 
includes inter-study variability, it may improve accuracy of results versus 
the probability integration model. However, due to the typical small 
number of studies included in microarray meta-analyses, the variability 
between studies is difficult to estimate. The probability integration model 
eliminates the need to specify inter-study variability since each study is 
modeled separately, and thus its implementation is more straightforward. 
Conlon and colleagues found that their probability integration model 
identified more true DEGs and fewer true omitted genes (i.e. genes 
declared as differentially expressed in individual studies but not in meta-
analysis) than combining expression values. 
Another meta-analysis method based on the modeling of the effect 
size within a Bayesian framework is that described by Wang and 
colleagues [25] and termed posterior mean differential expression. The 
main idea of their method is that one can use data from one study to 
construct a prior distribution of differential expression for each gene, 
whose distribution is then updated using other microarray studies thus 
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providing the posterior mean differential expression. The z statistics 
obtained weighting the posterior mean differential expression by 
individual studies’ variances, has a standard normal distribution due to 
classic Bayesian probability calculation and may be used to test the 
differential expression. Alternatively random permutations can be used to 
estimate the distribution of the z scores under the null hypothesis and to 
determine the significance of the observed statistics. 
3.4 COMBINING RANKS 
Methods combining robust rank statistics are used to contain the 
problem of outliers which affect the results obtained using methods 
combining p-values or effect sizes. This can be a significant problem when 
thousands of genes are analyzed simultaneously in the noisy nature of 
microarray experiments. Instead of p-values or effect sizes, the ranks of 
differentially expressed evidence are calculated for each gene in each 
study. The product [42], mean [133] or sum [134] of ranks from all studies 
is then calculated as the test statistics. Permutation analysis can be 
performed to assess the statistical significance and to control FDR.  
Zintzaras and Ioannidis [133] proposed METa-analysis of RAnked 
DISCovery datasets (METRADISC), which is based on the average of the 
standardized rank. METRADISC is the only rank-based method that 
incorporates and estimates the between-study heterogeneity. In addition 
the method can deal with genes which are measured in only some of the 
studies. The tested genes in each study are ranked based on the direction 
in expression change and the level of statistical significance or some other 
metrics. If there are G genes being tested, the highest rank G is given to 
the gene that shows the lowest p-value and is over-expressed in 
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treatment group (t) vs control group (c). The lowest rank 1 is given to the 
gene that shows the lowest p-value and is down-regulated in treatment 
group vs control group. Genes with equal p-values are assigned tied ranks. 
The average rank R* and the heterogeneity metric Q* for each gene g 
across studies are defined as: 
(24)   
  ∑    
 
    ⁄  
and 
(25)   
  ∑ (     
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where Rgi is the rank of the gene g for study i (i=1 to k studies). The 
statistical significance for R* and Q* for each gene is assessed against the 
distributions of the average ranks and heterogeneity metrics under the 
null hypothesis that ranks are randomly assigned. Null distributions are 
calculated using non-parametric Monte Carlo permutation method. In this 
method, in a run, the ranks of each study are randomly permutated and 
the simulated metrics are calculated. The procedure is repeated a number 
of times, depending on the required accuracy of the final p-values. 
Four statistical significance values are provided for each gene: 
statistical significance for high average rank, for low average rank, for high 
heterogeneity and for low heterogeneity. The statistical significance for 
high average rank is defined as the percentage of simulated metrics that 
exceed or are equal to the observed R*. The statistical significance for low 
average rank is the percentage of simulated metrics that are below or 
equal to the observed R*. Significance of heterogeneity is defined 
analogously. Interesting genes are those with significant average rank 
(either low or high) and low heterogeneity which indicates that the results 
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are consistent among different studies. The desired threshold of statistical 
significance for the R* and Q* testing should be selected on a case-by-case 
basis, depending on the desired trade-off between false negatives and 
false discovery rate. As a default, Zintzaras and Ioannidis recommend a 
level of 0.05/G, where G is the total number of genes shared by all the 
datasets, for average rank testing, and a less stringent p-value for 
heterogeneity-testing.  
The original version of METRADISC performs an unweighted analysis 
giving equal weight to all studies. Alternatively, one may weight each 
study by its total sample size or other weight functions depending on the 
type of data to be combined. For two-class comparisons a very common 
weight function is given by: 
(26)                        ⁄  
where nit and nic are the number of samples in groups t and c in study 
i, respectively. Then the weighted average rank for each gene across 
studies is defined as: 
(27)    
   ∑       
 
   ∑   
 
   ⁄  
Heterogeneity testing should instead be performed with unweighted 
analyses, so as small studies are allowed to show their differences against 
larger ones [135]. 
Hong and colleagues [42] proposed a modification and extension of 
the rank product method, which was initially introduced by Breitling and 
colleagues [136] to detect DEGs between two experimental conditions in a 
single study. The Fold-Change (FC) is chosen as a selection method to 
compare and rank the genes within each dataset. These ranks are then 
combined to produce an overall score for the genes across datasets, 
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obtaining a ranked gene list. The method focuses on genes which are 
consistently highly ranked in a number of datasets, for example genes that 
are regularly found among top up-regulated genes in many microarray 
studies. In detail, the algorithm of the method consists of five steps. 
1. For each gene g (g=1 to G genes), pair-wise ratios or FCs are 
calculated within each dataset i (i=1 to k studies). Let nti and nci be 
the number of samples in group 1 and 2 in study i, then the total 
number of pair-wise comparisons is equal to Li=nit*nic.  
2. Ranks are assigned (1 for the highest value) according to fold-
change ratio. Rgil is the rank of gene g in ith study under lth 
comparison, l=1…Li.  
3. RankProduct for each gene g is calculated as:  
(28)     (∏ ∏       )
 
  
where L is the sum of products of number of samples in groups: 
(29)   ∑          
 
    
The smaller the RP value the smaller the probability that the 
observation of the gene at the top of the lists is due to chance. It is 
equivalent to calculating the geometric mean rank. 
4. b permutations of gene expression values within each array are 
performed and all previous steps repeated in order to obtain the 
null rank product statistic    
    
. 
5. Step 4 is repeated B times to estimate the distribution of    
    
. 
This distribution is used to calculate p-value and FDR for each gene. 
(30)        ⁄  ∑ ∑  (    
           )     
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(31)      
   ⁄  ∑ ∑  (      
       )    
∑  (           )   
 
Converting FCs into ranks increased the results robustness against 
noise and across-studies heterogeneity as demonstrated by Yuen and 
colleagues [66]. In fact, they showed that although the FCs of DEGs had 
poor consistency across platforms, the rank orders were comparable. 
In a recent study, Hong and Breitling [109] comparatively evaluated 
rank product method, Fisher’s method and the t-based hierarchical 
modeling, showing that the rank product outperformed the other 
methods in terms of sensitivity and specificity, especially in the setting of 
small sample size and/or large between-study variation. 
The rank product method is implemented in the Bioconductor 
package RankProd [42]. 
DeConde and colleagues [137] proposed three aggregation 
approaches based on meta-search methods from computer science, which 
are used to combine ranked results from multiple internet search engines 
[138]. Because they rely on rank-ordered gene lists, they share many of 
the advantageous characteristics of rank products. In particular, two of 
the algorithms use Markov chains to convert the pair-wise preferences 
between the gene lists into a stationary distribution, representing an 
aggregate ranking, while the third algorithm is based on an order-statistics 
model. 
3.5 AVAILABLE SOFTWARE 
Despite the availability of many microarray meta-analysis methods, 
there exist very few software packages for microarray meta-analysis 
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implementation and most of them either did not have clear manuals or 
had functions that were not easy to apply.  
Compared with popular microarray data analysis packages (e.g. SAM, 
limma or BRB array tool), existing meta-analysis packages are relatively 
primitive and difficult to use. In the R and Bioconductor environment, 
metaGEM (which implements vote counting, Fisher's method and random 
effects model) [48], GeneMeta (which implements fixed and random 
effects model), metaMA (which implements random effects model and 
Stouffer’s method), metaArray (which implements three meta-analysis 
approaches: (1) probability of expression (POE) [90, 139], (2) integrative 
correlation [140] and (3) posterior mean differential expression [25]) [90], 
OrderedList (which compares ordered gene lists) [141], RankProd (that 
implements rank product method) [42] and RankAggreg (that implements 
various rank aggregation methods) [142] are available. The R package 
MAMA [Ihnatova I, 2012; MAMA: Meta-Analysis of MicroArray, R package 
version 2.1.0] was the first tool that implemented many different meta-
analysis methods. It uses a common framework to manage and combine 
the individual datasets. It additionally offers some functionalities to 
combine and visualize outputs from different methods, allowing a 
complex view on change in gene expression. 
Recently MetaOmics [143], a suite of three R packages MetaQC, 
MetaDE and MetaPath, for quality control, DEGs identification and 
enriched pathway detection for microarray meta-analysis, respectively, 
has been developed. The MetaQC package [144] provides a quantitative 
and objective tool to determine suitable study inclusion/exclusion criteria 
for meta-analysis. MetaDE contains many state-of the art meta-analysis 
methods to detect DEGs (Fisher, Stouffer, adaptively weighted Fisher 
(AW), minimum p-value, maximum p-value, rth ordered p-value (rOP) 
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[145], fixed and random effects model, rank product, naïve sum of ranks 
and naïve product of ranks [134]). Finally the MetaPath package [146] 
provides a unified meta-analysis framework and inference to detect 
enriched pathways associated with outcome. At present MetaOmics is the 
most complete software for microarray data meta-analysis and the only 
tool that provides a systematic pipeline to assist the user in conducting 
the meta-analysis. Information concerning the R and Bioconductor 
packages described above is summarized in Table 3.1. 
Package Environment  Reference Link 
metaGEM R 
[Ramasamy A 
et al., 2008] 
http://hdl.handle.net/10044/1/4217  
GeneMeta Bioconductor [Lusa L et al.,] http://www.bioconductor.org/packages/releas
e/bioc/html/GeneMeta.html 
metaMA R 
[Marot G et 
al., 2009] 
http://cran.r-
project.org/web/packages/metaMA/  
metaArray Bioconductor 
[Ghosh D and 
Choi H] 
http://www.bioconductor.org/packages/2.11/b
ioc/html/metaArray.html 
RankProd Bioconductor 
[Hong F et al., 
2006] 
http://www.bioconductor.org/packages/2.11/b
ioc/html/RankProd.html 
OrderedList Bioconductor 
[Lottaz C et 
al., 2009] 
http://www.bioconductor.org/packages/2.11/b
ioc/html/OrderedList.html 
RankAggreg R 
[Pihur H and 
Datta S, 2009] 
http://cran.r-
project.org/web/packages/RankAggreg/index.h
tml 
MAMA R 
[Ihnatova I, 
2010] 
http://cran.r-
project.org/web/packages/MAMA/index.html 
MetaOmics 
(MetaQC, 
MetaDE, 
MetaPath) 
R 
[Wang X et al., 
2012] 
http://cran.r-
project.org/web/packages/MetaQC/ 
http://cran.r-
project.org/web/packages/MetaDE/ 
http://cran.r-
project.org/web/packages/MetaPath/  
Table 3.1: Available R and Bioconductor packages for microarray data meta-analysis 
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4 APPLICATION TO REAL DATASETS 
We applied some of the meta-analysis methods described in the 
previous chapter to a set of three microarray experiments from four 
malignant pleural mesothelioma (MPM) studies. We focused on 
differential expression analysis between normal and malignant 
mesothelioma pleural tissues.  
4.1 MATERIALS AND METHODS 
4.1.1 DATA COLLECTION 
To systematically collect MPM microarray studies PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed) was searched with keywords 
related to the study background. The automatic search covered up to the 
end of December 2011. The search was extended to the two largest public 
microarray data repositories: GEO and ArrayExpress. MPM microarray 
studies suitable for meta-analysis were selected according to the following 
inclusion/exclusion criteria: 
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- any human studies investigating at least four patients with MPM 
and at least four patients with corresponding normal pleural 
samples using high-density arrays were included, 
- any studies using mesothelioma derived cell lines or studies using 
specialized arrays were excluded, 
- any studies where patients with MPM have been exposed to drugs 
were excluded.  
In the following, datasets will be referred to by the name of the ﬁrst 
author of the related papers.  
4.1.2 DATA PREPROCESSING 
The quality assessment of the raw data was performed using affyPLM 
[74] and arrayQualityMetrics [75] Bioconductor packages with the aim of 
identifying and possibly removing poor quality arrays and to detect 
possible systematic effects.  
All datasets were preprocessed independently for background 
correction, normalization and summarization. 
According to Ramasamy [48], who stated that the same 
preprocessing algorithm should be used for multiple studies conducted on 
the same platform, raw data from Crispi and Røe were preprocessed using 
the implementation of the Affymetrix MAS 5.0 algorithm provided by the 
Bioconductor package simpleaffy [73], setting the scale parameter to 100. 
Gene expression levels for each microarray in the Gordon study were 
generated and scaled to a target intensity of 100 using Affymetrix 
Microarray Suite v.5.0 (Santa Clara, USA). The log2 of the expression values 
was taken. 
Alternatively, in order to assess the overall effect of the 
preprocessing methods on meta-analysis results, for all the studies the 
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data preprocessed using the algorithm described by the original authors in 
their papers were also considered. In particular, probe set intensities were 
obtained by means of gcrma [147] followed by quantile normalization for 
Crispi dataset and by means of RMA (Robust Multi-array Average) [148] 
for Røe dataset. In both cases, the gene expression values of the technical 
replicates in the Røe dataset have been averaged after the preprocessing 
step. The assessment of data quality was repeated after the preprocessing 
step to check the normalization efficiency.  
Box plots and density plots for each sample in each dataset were 
used to evaluate the effect of the preprocessing steps on the data.  
4.1.3 DATA ANNOTATION 
To combine microarray data across studies a unique gene-level 
identifier must be adopted. We relied on official Gene Symbols by the 
HUGO Gene Nomenclature Committee [149] to achieve a uniform 
annotation across array versions. Affymetrix probe set IDs were mapped 
to the corresponding Gene Symbol IDs using platform-specific 
Bioconductor annotation packages such as hgu133a.db [Carlson M, 
hgu133a.db: Affymetrix Human Genome U133 Set annotation data (chip 
hgu133a). R package version 2.8.0], hgu133plus2.db [Carlson M, 
hgu133plus2.db: Affymetrix Human Genome U133 Plus 2.0 Array 
annotation data (chip hgu133plus2). R package version 2.8.0] and 
AnnotationDbi [Pages H, Carlson M et al., AnnotationDbi: Annotation 
Database Interface. R package version 1.20.3]. Probe set IDs with no Gene 
Symbol and probe set IDs mapping to more than one Gene Symbol were 
discarded from each dataset. Vice versa, when multiple probes sets 
mapped to an identical Gene Symbol, the probe set ID with the largest 
Inter Quartile Range (IQR) of expression values (among all multiple probe 
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IDs) was selected to represent the gene. Larger IQR represents greater 
variability (and thus greater information content) in the data and this 
probe matching method has been recommended in Bioconductor [74]. 
Only the genes in common between the three datasets were retained for 
the analysis. 
The gene expression values for the genes in common to all studies 
from the three datasets were bound together to form two final meta-
datasets, denoted as A and B, containing MAS 5.0 preprocessed data and 
data processed according to the original authors’ methods, respectively.  
Box plots and PCA plots of meta-datasets A and B were used to 
inspect for any clustering of arrays by studies. affy [150] and EMA (Easy 
Microarray data Analysis) [151] Bioconductor packages were used to 
obtain these plots. 
4.1.4 GENE FILTERING 
As stated in Chapter 2, it is unclear if filtering is beneficial from a 
meta-analysis perspective. Here we tried to evaluate the effect of a 
common filtering strategy on meta-analysis results. Two sequential steps 
of gene filtering were applied to meta-datasets A and B. In the first step, 
genes with very low expression showing small average expression values 
across studies were filtered out. Specifically, mean intensities of each gene 
across all samples in each study were calculated and the corresponding 
ranks were obtained. The sum of such ranks across the three studies of 
each gene was calculated and genes with the lowest 30% rank sum were 
considered unexpressed genes and were filtered out. Similarly, in the 
second step, genes with small variation between the experimental 
conditions were filtered out by replacing mean intensity in the first step 
with standard deviation. Genes with the lowest 30% rank sum of standard 
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deviations were filtered out. Finally only the genes which passed the two 
filtering steps were retained for further analysis. We denoted these 
additional filtered meta-datasets as A1 and B1. 
Box plots and PCA plots of datasets A1 and B1 were used to inspect 
for any clustering of arrays by studies. 
4.1.5 DATA META-ANALYSIS 
A combination of meta-analysis methods was applied to both 
unfiltered (A and B) and filtered (A1 and B1) meta-datasets. First of all, a 
standard limma analysis was performed including a study effect in the 
linear model. The Benjamini and Hochberg (BH) multiple correction 
method with a threshold of 5% was applied to identify the DEGs. In 
addition three meta-analysis approaches were applied to the meta-
datasets:  
1. the weighted inverse normal p-value combination method 
proposed by Marot and colleagues [40] and implemented in the R 
package metaMA. Both the standard t-statistics and the moderated 
t-statistics were used to calculate the p-values for each gene in the 
individual studies analyses. We will refer to this method as p-value 
combination method. 
2. The effect size combination approach both in the Choi and 
colleagues’ version [16], implemented in the Bioconductor package 
GeneMeta, and in the Marot and colleagues’ version [40], available 
in the R package metaMA. We will refer to these methods as the 
GeneMeta and the metaMA method, respectively.  
3. The rank combination method by Hong and colleagues [42], 
implemented in the Bioconductor package RankProd. We will refer 
to this methods as RankProd method. 
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The DEGs were selected at significance level of 0.05 in all methods. 
In order to the selected DEGs lists from different methods be more 
comparable in size, we considered the lists of the top 500 genes with the 
smallest p-values/q-values for each method. 
All analysis was carried out in R version 2.15.2 and Bioconductor 
release 2.11. 
To further assess the DEGs lists produced by the different methods, 
pathway analysis was done using PathwayExpress [152]. Hypergeometric 
distribution and FDR were used for the p-value calculation and p-value 
correction, respectively. The set of genes shared by all the three datasets 
was selected as reference array for the over-representation analysis. The 
magnitude of the measured expression changes was not used because this 
information was not available for all the tested methods. 
4.2 RESULTS  
Only four microarray studies [153-156] met the inclusion/exclusion 
criteria. This may depend on the difﬁculty of collecting a large number of 
tissue samples, due to the low incidence of MPM. However the two 
papers by Røe and colleagues referred to the same dataset so there were 
only three distinct datasets suitable for the meta-analysis. 
By querying ArrayExpress and GEO, the raw data (in the form of CEL 
files) were retrieved for Crispi and Røe studies but not for Gordon study 
for which only gene expression data have been deposited in GEO 
database. The authors were asked for the raw data but they did not make 
them available. 
The studies were performed on different versions of the Affymetrix 
oligonucleotide microarray platform. The Crispi and Røe studies used 
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Affymetrix Human Genome U133 Plus2.0 GeneChip (Santa Clara, CA, USA), 
containing 54675 probe sets, each with eleven probe pairs. The Crispi 
dataset included thirteen samples, four normal pleural samples and nine 
MPM samples. The Røe dataset consisted of one papillary serous 
adenocarcinoma pleura sample, one pleural plaque sample with unknown 
disease condition, seven MPM samples, where two were from the same 
patient, seven parietal pleural samples, where two were from the same 
patient, and four visceral pleural samples that were from the same control 
patients. Finally, the Gordon study was performed on Affymetrix Human 
Genome U133A GeneChip, containing 22283 probe sets, each with eleven 
probe pairs. This dataset included forty human MPM tumor specimens, 
five normal pleura specimens, four normal lung specimens and five 
mesothelial cell lines, where four are MPM derived and one (Met5a) is a 
nontumorigenic immortalized mesothelial cell line. The papillary serous 
adenocarcinoma sample and the pleural plaque sample with unknown 
disease condition in the Røe dataset were discarded. Moreover the four 
visceral pleural samples were excluded from the meta-analysis according 
to the authors. They observed that mesothelioma, parietal and visceral 
pleural tissues show distinct expression profiles and parietal pleura can be 
considered as the main reference because mesothelioma usually develops 
in the parietal pleura, subsequently invading the visceral layer [155]. 
Similarly, only the forty human MPM tumor specimens and the five normal 
pleural specimens in the Gordon dataset were retained for the meta-
analysis. 
The main features of the three datasets included in the meta-analysis 
after excluding unsuitable samples are summarized in Table 4.1. 
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Authors 
Repository 
(Accession 
Number) 
Normal Tumor Platform 
Total 
Probes  
Probes 
with 
Gene  
Symbols 
Crispi et al.  
(2009) 
GEO 
4 9 HGU133Plus2 54675 41910 
(GSE12345) 
Røe et al.  
(2010) 
ArrayExpress 
(E-MTAB-47) 
7 7 HGU133Plus2 54675 41910 
Gordon et al. 
(2005) 
GEO 
(GSE2549) 
5 40 HGU133A 22283 20365 
Table 4.1: Microarray datasets and samples included in the meta-analysis 
 
Figure 4.1 and Figure 4.2 show the box plots of MAS 5.0 
preprocessed, log2 transformed gene expression data separately for the 
three datasets, while box plots of preprocessed data obtained applying 
different algorithms for each dataset are shown in Figure 4.2 and Figure 
4.3. 
 
Figure 4.1: Box plots of MAS 5.0 preprocessed data from Crispi (left) and Røe 
(right) datasets (red=MPM samples, blue=control samples) 
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Figure 4.2: Box plots of MAS 5.0 preprocessed data from Gordon dataset 
(red=MPM samples, blue=control samples) 
 
 
Figure 4.3: Box plots of data preprocessed using the algorithms described by 
individual authors, gcrma for Crispi dataset (left) and RMA for Røe dataset (right) 
(red=MPM samples, blue=control samples) 
 
In both cases, the preprocessed data from the three studies were 
matched using Gene Symbol IDs. By excluding the control probe sets, the 
22215 probe sets in the U133A platform mapped to 20365 Gene Symbols, 
while the 54613 probe sets in the U133 Plus 2.0 platform mapped to 
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41910 Gene Symbols. After solving the many-to-many relationships, 
12701 and 20184 unique Gene Symbols were found in the U133A and 
U133 Plus 2.0 platform, respectively. Only the 12701 genes in common to 
all three datasets were kept for the meta-analysis. Consequently the 
meta-datasets A and B consist of 12701 genes and 70 samples.  
After the filtering steps, 6222 matched genes in three studies were 
analyzed. The meta-datasets A1 and B1 consist of 6222 genes and 70 
samples. We note that the somewhat ad hoc gene filtering procedure is 
necessary and is commonly used in microarray analysis. This procedure 
can reduce false positives from non-expressed or non-informative genes 
and increase statistical power in multiple test correction; however 
important DEGs can be discarded. Figure 4.4 shows the preprocessing 
diagram and the number of genes selected by each preprocessing step. 
 
Figure 4.4: A diagram for data preprocessing, gene matching and gene filtering 
 
PCA plots for the meta-datasets A and B are reported in Figure 4.5. In 
both cases, PCA plots highlight a clustering of arrays by studies. 
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Figure 4.5: PCA plots of MAS 5.0 preprocessed data (left) and data preprocessed 
using the algorithms described by individual authors (right) (common Gene Symbols 
only) (red=Crispi dataset, blue= Røe e dataset, green=Gordon dataset) 
 
The same grouping of arrays by studies is evident from the box plots 
(see Figure 4.6 and Figure 4.7). However the box plots highlight better 
how the differences between the studies are relevant when the data 
preprocessed using different algorithms for the three datasets are 
considered compared to the MAS 5.0 processed data. Figure 4.6 also 
suggests a possible ‘platform effect’ as the Crispi and Røe datasets, 
performed on the same Affymetrix platform, appear much more similar to 
each other than to the data from the Gordon study performed on a 
different Affymetrix platform. 
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Figure 4.6: Box plots of MAS 5.0 preprocessed data (common Gene Symbols 
only) (red=Crispi dataset, blue= Røe dataset, green=Gordon dataset) 
 
 
Figure 4.7: Box plots of data preprocessed using the algorithms described by 
individual authors (common Gene Symbols only) (red=Crispi dataset, blue= Røe 
dataset, green=Gordon dataset) 
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The same considerations apply to meta-datasets A1 and B1, whose 
PCA plots and box plots are shown in Figure 4.8, Figure 4.9 and Figure 
4.10. 
 
Figure 4.8: PCA plots of MAS 5.0 preprocessed data (left) and data preprocessed 
using the algorithms described by individual authors (right) after filtering (common 
Gene Symbols only) (red=Crispi dataset, blue= Røe dataset, green=Gordon dataset) 
 
 
Figure 4.9: Box plots of MAS 5.0 preprocessed data after filtering (common Gene 
Symbols only) (red=Crispi dataset, blue= Røe dataset, green=Gordon dataset) 
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Figure 4.10: Box plots of data preprocessed using the algorithms described by 
individual authors after filtering (common Gene Symbols only) (red=Crispi dataset, 
blue= Røe dataset, green=Gordon dataset) 
 
Concerning meta-dataset A, at a 5% BH threshold, using a limma 
model including a study effect, 1883 genes were found statistically 
significant. The p-value combination claimed 2420 and 2461 genes as 
differentially expressed at the same BH threshold using the moderated t-
statistics and the standard t-statistics, respectively. For the metaMA 
method, 698 and 610 genes were found as differentially expressed at a 5% 
BH threshold using the moderated t-statistics and the standard t-statistics, 
respectively. The GeneMeta method identified 717 DEGs at a 5% BH 
threshold using the REM. The Cochran’s Q statistics has been used to test 
the between-study variability and decide between the REM and the FEM. 
Using the SAM type analysis to estimate the FDR, 1154 DEGs were 
identified with a FDR<0.05 for the two-sided hypothesis. These 1154 DEGs 
included the 717 DEGs identified using the BH multiple correction 
procedure. Finally, the RankProd method detected 1110 DEGs. The 
number of DEGs identified by each method for meta-datasets A and B is 
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summarized in Table 4.2, while the meta-analysis results for the filtered 
meta-datasets A1 and B1 are illustrated in Table 4.3. 
  
limma 
with 
study 
effect 
P-value  
combination 
metaMA  
approach 
GeneMeta 
approach 
RankProd 
    
stand. 
T 
moder. 
T 
stand. 
t 
moder. 
T 
REM REM_FDR   
dataset A 1883 2461 2420 610 698 717 1154 1110 
dataset B 2066 2627 2691 871 947 994 1437 1309 
intersection 1446 2024 2002 470 511 546 839 1031 
intersection/ 
(A only+B only -
intersection) % 
57.77 66.06 64.39 46.49 45.06 46.87 47.89 74.28 
Table 4.2: Number of DEGs provided by the different meta-analysis approaches 
at 5% BH threshold for both datasets A and B and their intersections 
 
  
limma 
with 
study 
effect 
P-value  
combination 
metaMA  
approach 
GeneMeta 
approach 
RankProd 
    
stand. 
T 
moder. 
t 
stand. 
t 
moder. 
T 
REM REM_FDR   
dataset A1 1485 1684 1699 559 626 627 912 668 
dataset B1 1548 1787 1805 667 742 717 1018 735 
intersection 1095 1291 1293 382 428 423 619 511 
intersection/ 
(A1 only+B1 only -
intersection) % 
56.5 59.22 58.48 45.26 45.53 45.93 47.22 57.29 
Table 4.3: Number of DEGs provided by the different meta-analysis approaches 
at 5% BH threshold for both datasets A1 and B1 and their intersections 
 
Venn diagrams corresponding to the comparisons of these methods 
applied to meta-dataset A are given in Figure 4.11 and Figure 4.12.  
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Figure 4.11: Venn diagram for meta-dataset A comparing the DEGs lists at a 5% 
BH threshold obtained by combining p-values, effect sizes (using both metaMA and 
GeneMeta approaches) and ranks  
 
 
Figure 4.12: Venn diagram for meta-dataset A comparing the DEGs in common 
between the four meta-analysis methods to the DEGs list provided by limma including 
a study effect  
 
It was found that 281 DEGs were in common between the four 
approaches (gray sector in Figure 4.11). This poor overlap is mainly due to 
the DEGs identified by the RankProd method which look quite different 
from the DEGs lists generated by the other meta-analysis approaches. In 
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fact, excluding the RankProd method, the number of DEGs in common 
between the other three approaches goes up to 696 (see Figure 4.13). 
 
Figure 4.13: Venn diagram comparing the DEGs lists at a 5% BH threshold 
obtained by combining p-values and effect sizes (using both metaMA and GeneMeta 
approaches) for meta-dataset A. 
 
It can also be noticed that the p-value combination method detected 
all the genes found with the metaMA effect size combination method, all 
but 49 genes found with the GeneMeta method followed by SAM type 
analysis to estimate the FDR and all but 275 genes identified by the 
RankProd method. On the other hand, 853 genes were detected only by 
the p-value combination method. For each method the intersections 
among the identified DEGs for meta-datasets A and B and A1 and B1 are 
summarized in Table 4.2 and Table 4.3, respectively.  
Since many biological replicates were involved, we could not observe 
on these datasets the gain of DEGs usually found with shrinkage 
approaches. Indeed, the effect size combination based on classical t-tests 
detected 610 DEGs while the effect size combination based on moderated 
t-tests found 698 DEGs. We could check that, in this case, using the exact 
variance for standard effect sizes, as done by the metaMA method, the 
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number of DEGs did not change substantially compared with using the 
asymptotic variance, as done by GeneMeta. Indeed, the effect size 
combination based on usual t-tests and the exact variance detected 610 
DEGs, while the z-score given by the GeneMeta package found 717 DEGs. 
Table 4.2 also points out that p-value combination method detected many 
more genes than the other approaches. The same considerations apply to 
the meta-datasets B, A1 and B1. Concerning the intersections between the 
DEGs lists detected by the diverse methods in the meta-datasets A and B, 
it is worth noting that the greater overlap (74.28 %) was reached by the 
RankProd method thus confirming the reduced dependence of this 
approach by the preprocessing methods adopted in single-study analysis 
and its greater robustness against heterogeneity across studies [66]. The 
intersections between the DEGs lists detected by the different methods in 
the meta-datasets A1 and B1 are instead comparable in size.  
As far as gene rankings were concerned, they were very similar. The 
absolute values of test statistics used by the different meta-analysis 
methods were ranked in descending order and the Spearman rank 
correlation coefficients were calculated for each pair of methods. Detailed 
results for meta-datasets A and B are summarized in Table 4.4 and Table 
4.5, respectively. As expected, the highest correlation (0.99) was found 
between GeneMeta and metaMA methods given the similarity between 
the used summary test statistics. Slightly lower values were obtained for 
meta-dataset B. Concerning meta-datasets A1 and B1, a slight increase of 
the correlation coefficients can be observed. Spearman rank correlation 
coefficients for dataset A1 are summarized in Table 4.8. 
In order to make the DEGs lists from different methods more 
comparable in size, the top 500 DEGs for all the methods were selected. 
 
68 
Figure 4.14 and Figure 4.15 are Venn diagrams displaying the overlap of 
the top 500 DEGs found by different methods applied to meta-dataset A. 
 
Figure 4.14: Venn diagram showing the overlap of the top 500 DEGs found by 
different meta-analysis methods applied to meta-dataset A 
 
 
Figure 4.15: Venn diagram showing the overlap of the top 500 DEGs in common 
between the four meta-analysis methods and the top 500 DEGs found by limma 
including a study effect applied to meta-dataset A 
 
Detailed information concerning the size of the overlap between the top 
500 DEGs lists found using the different meta-analysis methods for 
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datasets A, B and A1 are presented in Table 4.6, Table 4.7 and Table 4.9, 
respectively. Also in this case, the use of the filtering process results in a 
greater overlap of the results provided by the different meta-analysis 
methods. 
The fact that a significant number of genes were selected by only one 
of the methods shows that the gene ranking is based on different 
perspectives, thus it may be useful to select candidate genes using a 
combination of these methods. 
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limma with 
study effect 
P-value combination  metaMA approach 
GeneMeta 
approach 
RankProd 
      standard t moderated t standard t moderated t REM_FDR   
limma with 
study effect   1 
      P-value 
combination 
standard t 0.883 1 
     moderated t 0.897 0.994 1 
    metaMA 
approach 
standard t 0.883 0.836 
 
1 
   moderated t 0.898  0.831 0.993 1 
  GeneMeta 
approach 
REM_FDR 0.88 0.823 0.82 0.999 0.993 1 
 RankProd   0.768 0.687 0.717 0.78 0.81 0.785 1 
   Table 4.4: Spearman rank correlations for meta-dataset A 
 
  
limma with 
study effect 
P-value combination  metaMA approach 
GeneMeta 
approach 
RankProd 
      standard t moderated t standard t moderated t REM_FDR   
limma with 
study effect   1 
      P-value 
combination 
standard t 0.904 1 
     moderated t 0.92 0.995 1 
    metaMA 
approach 
standard t 0.772 0.832 
 
1 
   moderated t 0.783 
 
0.833 0.99 1 
  GeneMeta 
approach 
REM_FDR 0.684 0.717 0.717 0.863 0.845 1 
 RankProd   0.882 0.754 0.782 0.74 0.761 0.637 1 
   Table 4.5: Spearman rank correlations for meta-dataset B  
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limma with 
study effect 
P-value combination  metaMA approach 
GeneMeta 
approach 
RankProd 
      standard t moderated t standard t moderated t REM_FDR   
limma with 
study effect   100 
      P-value 
combination 
standard t 76.2 100 
     moderated t 78.6 
 
100 
    metaMA 
approach 
standard t 64.4 54.6 
 
100 
   moderated t 65 
 
54.8 
 
100 
  GeneMeta 
approach 
REM_FDR 63.4 53.6 52.8 96.4 86.6 100 
 RankProd   33.6 37.6 42.2 23.6 23.8 22.6 100 
Table 4.6: Overlap between the top 500 DEGs lists identified by various methods for meta-dataset A, expressed as a percentage 
 
  
limma with 
study effect 
P-value combination  metaMA approach 
GeneMeta 
approach 
RankProd 
      standard t moderated t standard t moderated t REM_FDR   
limma with 
study effect   100 
      P-value 
combination 
standard t 75.8 100 
     moderated t 78 
 
100 
    metaMA 
approach 
standard t 57.6 54 
 
100 
   moderated t 56.6 
 
56.8 
 
100 
  GeneMeta 
approach 
REM_FDR 55.8 52.2 53 95.4 93 100 
 RankProd   37.4 40.8 43 25.4 25.8 24.2 100 
Table 4.7: Overlap between the top 500 DEGs lists identified by various methods for meta-dataset B, expressed as a percentage 
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limma with 
study effect 
P-value combination  metaMA approach 
GeneMeta 
approach 
RankProd 
      standard t moderated t standard t moderated t REM_FDR   
limma with 
study effect   1 
      P-value 
combination 
standard t 0.922 1 
     moderated t 0.935 0.996 1 
    metaMA 
approach 
standard t 0.874 0.848 
 
1 
   moderated t 0.883 
 
0.846 0.996 1 
  GeneMeta 
approach 
REM_FDR 0.869 0.837 0.837 0.999 0.996 1 
 
RankProd   0.892 0.763 0.79 0.806 0.829 0.808 1 
Table 4.8: Spearman rank correlations for meta-dataset A1 
 
  
limma with 
study effect 
P-value combination  metaMA approach 
GeneMeta 
approach 
RankProd 
      standard t moderated t standard t moderated t REM_FDR   
limma with 
study effect   100 
      P-value 
combination 
standard t 81.2 100 
     moderated t 84.2 
 
100 
    metaMA 
approach 
standard t 64 56  100 
   moderated t 63.2  57.8 
 
100 
  GeneMeta 
approach 
REM_FDR 63.2 54.8 56.4 97 94.2 100 
 RankProd   47.8 49.4 54 36.4 37.4 35.6 100 
Table 4.9: Overlap between the top 500 DEGs lists identified by various methods for meta-dataset A1, expressed as a percentage 
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4.2.1 COMPARISONS AMONG THE DEGs LISTS AT PATHWAY-LEVEL 
To further assess the DEGs lists, a pathway analysis was performed. 
Table 4.10 shows the top five ranked pathways for the 75 and 79 DEGs 
(among the top 500 genes) that were selected by all methods simultaneously 
for meta-datasets A and B, respectively. Table 4.11 shows the top five ranked 
pathways for the 133 and 129 DEGs (among the top 500 genes) that were 
selected by all methods simultaneously for meta-datasets A1 and B1, 
respectively. 
Dataset A 
Pathway Name Impact Factor p-value corrected p-value 
Asthma 4,59 0,01 0,14 
Hematopoietic cell lineage 4,35 0,01 0,14 
Apoptosis 4,31 0,01 0,14 
Toll-like receptor signaling pathway 4,04 0,02 0,14 
Graft-versus-host disease 4,02 0,02 0,14 
    Dataset B 
Pathway Name Impact Factor p-value corrected p-value 
DNA replication 3,97 0,02 0,32 
Tight junction 3,27 0,04 0,32 
Epithelial cell signaling in Helicobacter pylori infection 2,93 0,05 0,32 
Non-homologous end-joining 2,55 0,08 0,32 
ECM-receptor interaction 2,40 0,09 0,32 
Table 4.10: Pathway analysis results for meta-datasets A and B considering the top 
500 DEGs selected by all the methods simultaneously 
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Dataset A1 
Pathway Name Impact Factor p-value corrected p-value 
Cell adhesion molecules (CAMs) 8,92 1,33E-04 0,01 
Neuroactive ligand-receptor interaction 6,28 0,00 0,04 
Renin-angiotensin system 5,05 0,01 0,09 
ECM-receptor interaction 4,27 0,01 0,14 
Tight junction 3,77 0,02 0,17 
    Dataset B1 
Pathway Name Impact Factor p-value corrected p-value 
Neuroactive ligand-receptor interaction 8,91 1,35E-04 0,00 
ECM-receptor interaction 6,21 0,00 0,03 
Cell adhesion molecules (CAMs) 5,00 0,01 0,07 
Tight junction 3,29 0,04 0,29 
Non-homologous end-joining 2,52 0,08 0,44 
Table 4.11: Pathway analysis results for meta-datasets A1 and B1 considering the 
top 500 DEGs selected by all the methods simultaneously 
 
Table 4.12 and Table 4.13 show the most perturbed KEGG pathways for 
the top 500 DEGs that were selected by each method, applied to meta-
datasets A and B, respectively. Analogous information for datasets A1 and B1 
is summarized in Table 4.14 and Table 4.15. A better agreement between the 
top pathways for the four meta-analysis approaches and between them and 
the top pathways provided by the intersection of all the methods was 
observed in the case of filtered datasets A1 and B1 compared to datasets A 
and B.  
Despite the poor overlap of the results at the gene-level, pathway 
analysis showed a higher concordance. Moreover the differences among the 
DEGs lists for meta-datasets A and B were confirmed at the pathway-level. In 
fact, although some pathways such as PPAR signaling pathway, complement 
and coagulation cascades and cytokine-cytokine receptor interaction were 
identified in both datasets by two or more meta-analysis methods, the 
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ranking is quite different and there are also some pathways unique for each 
dataset (e.g. apoptosis pathway detected only in dataset A and neuroactive 
ligand-receptor interaction and cell adhesion molecules (CAMs) pathways 
retrieved only in dataset B). Furthermore it is worth noting that the impact 
factors (the FDR-corrected p-values) for the top pathways by the RankProd 
method are higher (respectively, lower) compared to all the other methods in 
all meta-datasets. A higher impact factor indicates that the top genes lists 
contain genes that aggregate into certain functions as opposed to individual 
genes that are unrelated. Thus results with higher impact factor may make 
more sense and be more easily interpretable.  
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DEG_limma_with_study_effect 
Pathway Name Impact Factor p-value corrected p-value 
PPAR signaling pathway 8,88 1,39E-04 0,01 
Complement and coagulation cascades 5,47 0,00 0,17 
Apoptosis 4,05 0,02 0,35 
Renin-angiotensin system 3,77 0,02 0,35 
Thyroid cancer 3,66 0,03 0,35 
    DEGs_p-value combination (moderated t-statistics) 
Pathway Name Impact Factor p-value corrected p-value 
PPAR signaling pathway 8,88 1,39E-04 0,01 
Hematopoietic cell lineage 6,50 0,00 0,06 
Adipocytokine signaling pathway 4,54 0,01 0,28 
ECM-receptor interaction 4,26 0,01 0,28 
Cytokine-cytokine receptor interaction 3,85 0,02 0,29 
    DEGs_metaMA (moderated t-statistics) 
Pathway Name Impact Factor p-value corrected p-value 
Complement and coagulation cascades 9,95 4,76E-05 0,00 
Renin-angiotensin system 8,17 2,82E-04 0,01 
Hematopoietic cell lineage 5,25 0,01 0,14 
Cell adhesion molecules (CAMs) 4,93 0,01 0,15 
Apoptosis 4,05 0,02 0,28 
    DEGs_GeneMeta (FDR) 
Pathway Name Impact Factor p-value corrected p-value 
Renin-angiotensin system 5,82 0,00 0,15 
Complement and coagulation cascades 5,47 0,00 0,15 
Apoptosis 5,17 0,01 0,15 
DNA replication 4,60 0,01 0,16 
Cytokine-cytokine receptor interaction 4,57 0,01 0,16 
    DEGs_RankProd 
Pathway Name Impact Factor p-value corrected p-value 
ECM-receptor interaction 11,10 1,51E-05 0,00 
PPAR signaling pathway 8,88 1,39E-04 0,01 
Focal adhesion 6,48 0,00 0,04 
Adipocytokine signaling pathway 5,86 0,00 0,06 
Systemic lupus erythematosus 4,92 0,01 0,11 
Table 4.12: Pathway analysis results for meta-dataset A  
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DEGs_limma_with_study_effect 
Pathway Name Impact Factor p-value corrected p-value 
PPAR signaling pathway 8,88 1,39E-04 0,01 
Cell adhesion molecules (CAMs) 5,99 0,00 0,07 
Adipocytokine signaling pathway 5,86 0,00 0,07 
Hematopoietic cell lineage 5,25 0,01 0,10 
ECM-receptor interaction 4,26 0,01 0,19 
    DEGs_p-value combination (moderated t-statistics) 
Pathway Name Impact Factor p-value corrected p-value 
PPAR signaling pathway 8,88 1,39E-04 0,01 
Cell adhesion molecules (CAMs) 5,99 0,00 0,07 
Adipocytokine signaling pathway 5,86 0,00 0,07 
Hematopoietic cell lineage 5,25 0,01 0,10 
ECM-receptor interaction 4,26 0,01 0,19 
    DEGs_metaMA (moderated t-statistics) 
Pathway Name Impact Factor p-value corrected p-value 
Complement and coagulation cascades 8,35 2,37E-04 0,02 
Cell adhesion molecules (CAMs) 5,99 0,00 0,10 
PPAR signaling pathway 4,54 0,01 0,28 
ECM-receptor interaction 4,26 0,01 0,28 
Vibrio cholerae infection 3,89 0,02 0,30 
    DEGs_GeneMeta (FDR) 
Pathway Name Impact Factor p-value corrected p-value 
Complement and coagulation cascades 8,35 2,37E-04 0,02 
Cell adhesion molecules (CAMs) 5,99 0,00 0,10 
Vibrio cholerae infection 5,19 0,01 0,14 
ABC transporters 4,36 0,01 0,22 
ECM-receptor interaction 4,26 0,01 0,22 
    DEGs_RankProd 
Pathway Name Impact Factor p-value corrected p-value 
ECM-receptor interaction 11,10 1,51E-05 0,00 
PPAR signaling pathway 7,31 0,00 0,03 
Focal adhesion 6,48 0,00 0,04 
Cell adhesion molecules (CAMs) 4,93 0,01 0,11 
Systemic lupus erythematosus 4,92 0,01 0,11 
Table 4.13: Pathway analysis results for meta-dataset B 
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DEGs_limma_with_study_effect 
Pathway Name Impact Factor p-value corrected p-value 
Renin-angiotensin system 7,52 5,42E-04 0,04 
Neuroactive ligand-receptor interaction 6,55 0,00 0,05 
Cell adhesion molecules (CAMs) 5,74 0,00 0,07 
Cytokine-cytokine receptor interaction 5,59 0,00 0,07 
PPAR signaling pathway 4,79 0,01 0,12 
    DEGs_p-value combination (moderated t-statistics) 
Pathway Name Impact Factor p-value corrected p-value 
PPAR signaling pathway 6,23 0,00 0,13 
Cell adhesion molecules (CAMs) 5,74 0,00 0,13 
Renin-angiotensin system 4,76 0,01 0,19 
Cytokine-cytokine receptor interaction 4,65 0,01 0,19 
Neuroactive ligand-receptor interaction 4,08 0,02 0,23 
    DEGs_metaMA (moderated t-statistics) 
Pathway Name Impact Factor p-value corrected p-value 
Neuroactive ligand-receptor interaction 6,55 0,00 0,09 
Cell adhesion molecules (CAMs) 5,74 0,00 0,09 
Cytokine-cytokine receptor interaction 5,59 0,00 0,09 
Complement and coagulation cascades 5,38 0,00 0,09 
Renin-angiotensin system 4,76 0,01 0,14 
    DEGs_GeneMeta (FDR) 
Pathway Name Impact Factor p-value corrected p-value 
Cell adhesion molecules (CAMs) 5,74 0,00 0,14 
Complement and coagulation cascades 5,38 0,00 0,14 
Neuroactive ligand-receptor interaction 5,25 0,01 0,14 
Renin-angiotensin system 4,76 0,01 0,17 
Cytokine-cytokine receptor interaction 3,78 0,02 0,36 
    DEGs_RankProd 
Pathway Name Impact Factor p-value corrected p-value 
ECM-receptor interaction 14,05 7,89E-07 5,84E-05 
Focal adhesion 11,35 1,18E-05 4,35E-04 
Cytokine-cytokine receptor interaction 10,16 3,87E-05 9,56E-04 
PPAR signaling pathway 9,56 7,07E-05 0,00 
Neuroactive ligand-receptor interaction 6,55 0,00 0,02 
Table 4.14: Pathway analysis results for meta-dataset A1 
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DEGs_limma_with_study_effect 
Pathway Name Impact Factor p-value corrected p-value 
PPAR signaling pathway 9,89 5,08E-05 0,00 
Cell adhesion molecules (CAMs) 6,29 0,00 0,07 
Neuroactive ligand-receptor interaction 5,89 0,00 0,07 
Adipocytokine signaling pathway 4,26 0,01 0,28 
ECM-receptor interaction 3,81 0,02 0,35 
    DEGs_p-value combination (moderated t-statistics) 
Pathway Name Impact Factor p-value corrected p-value 
PPAR signaling pathway 8,10 3,03E-04 0,02 
Cell adhesion molecules (CAMs) 6,29 0,00 0,07 
Neuroactive ligand-receptor interaction 4,39 0,01 0,28 
Adipocytokine signaling pathway 4,26 0,01 0,28 
ECM-receptor interaction 3,81 0,02 0,35 
    DEGs_metaMA (moderated t-statistics) 
Pathway Name Impact Factor p-value corrected p-value 
Neuroactive ligand-receptor interaction 9,40 8,28E-05 0,01 
Leukocyte transendothelial migration 6,14 0,00 0,08 
Cell adhesion molecules (CAMs) 5,16 0,01 0,15 
Complement and coagulation cascades 4,26 0,01 0,28 
DNA replication 3,59 0,03 0,43 
    DEGs_GeneMeta (FDR) 
Pathway Name Impact Factor p-value corrected p-value 
Neuroactive ligand-receptor interaction 9,40 8,28E-05 0,01 
DNA replication 6,71 0,00 0,05 
Complement and coagulation cascades 5,58 0,00 0,10 
Cell adhesion molecules (CAMs) 4,13 0,02 0,29 
Leukocyte transendothelial migration 4,02 0,02 0,29 
    DEGs_RankProd 
Pathway Name Impact Factor p-value corrected p-value 
ECM-receptor interaction 15,93 1,20E-07 8,90E-06 
Focal adhesion 10,19 3,77E-05 0,00 
PPAR signaling pathway 9,89 5,08E-05 0,00 
Neuroactive ligand-receptor interaction 9,40 8,28E-05 0,00 
Cell adhesion molecules (CAMs) 8,84 1,46E-04 0,00 
Table 4.15: Pathway analysis results for meta-dataset B1 
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4.3 DISCUSSION 
The increasing availability and maturity of DNA microarray 
technology has led to an explosion of profiling studies, especially in cancer 
research. To extract maximum value from the accumulating mass of 
publicly available cancer gene expression data, methods are needed to 
evaluate, integrate, and inter-validate multiple datasets. Therefore, we 
applied a combination of statistical methods to perform a meta-analysis of 
independent microarray datasets in MPM tumor.  
A relevant number of studies on gene expression in MPM have been 
published so far. Gene expression profiling microarrays have been widely 
used in mesothelioma research to improve histological classifications 
[157], to identify predictive or prognostic biomarkers [158, 159] or to 
examine response to therapy [160]. One of the problems identified with 
the use of microarray technology and particularly in experiments involving 
MPM samples, has been the lack of concordance between the several 
studies. From this, one can conclude that microarray analysis of MPM 
would appear to be very ‘noisy’, and the differential expression of the 
identified genes should be confirmed independently at the RNA (RT-qPCR) 
or protein level (immunohistochemistry) [161]. There are several potential 
reasons for the low concordance of these studies such as different sample 
types (e.g. mesothelioma derived cell lines or mesothelioma patient 
samples) and/or histological subtypes, array platforms and number of 
samples. Therefore, a comparison of the results of individual analyses is 
not enough to evaluate the available gene expression data. Gene 
expression data often lack statistical power especially due to low sample 
size, as is the case in most of MPM microarray studies. This might depend 
on the low incidence of MPM in addition to the costs of the technology 
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and generally leads to underestimation of variances, which inflates the 
false-positive rate. Meta-analysis thus represents a good solution to 
overcome the problem of reduced statistical power of MPM microarray 
experiments and a valuable alternative for cross-study validation.  
The quality of the meta-analysis benefits from the number and the 
quality of single datasets analyzed. Focusing on differential expression 
analysis between normal and malignant pleural mesothelioma tissues, 
only three microarray studies compliant with our inclusion/exclusion 
criteria were identified and included in the meta-analysis. All the selected 
studies were performed on two different array versions of the same 
Affymetrix platform. We tried to obtain raw data for all of them but only 
the two most recent studies (Crispi and Røe) have the CEL files stored in 
public databases. For the Gordon study only MAS 5.0 preprocessed gene 
expression data were publicly available and this might heavily affect the 
down-stream analysis. In fact, to obtain consistently preprocessed data, 
the implementation of the MAS 5.0 algorithm provided by the 
Bioconductor package simpleaffy was used to process Crispi and Røe 
datasets. This choice has two limitations. On the one hand, there may be 
some not negligible differences between the expression data provided by 
the original MAS 5.0 algorithm and its re-implementation. On the other 
hand, in the last years new preprocessing methods, such as RMA and 
gcrma, have been developed that outperform MAS 5.0 in terms of 
sensitivity and specificity (i.e. the true and false detection rate) [162], 
especially for the detection of DEGs [163]. Despite the use of the same 
preprocessing method, our data showed a strong between-study 
variability. Gene expression data obtained applying to each dataset the 
preprocessing algorithms suggested by the original authors were also 
considered for the meta-analysis with the aim to evaluate the impact of 
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the preprocessing methods on the meta-analysis results. In addition, the 
number of genes evaluated was reduced applying an intensity filter 
followed by an IQR filter in order to eliminate non-expressed or non-
informative genes and increase statistical power in multiple comparison 
procedure. 
To date only two papers by Hong and colleagues [109] and Campain 
and colleagues [99] performed a systematic comparative analysis on 
microarray meta-analysis methods performances, in terms of sensitivity 
and specificity. Although the two studies provided insightful conclusions, 
the number of methods compared (three and five methods, respectively) 
and the number of case studies examined (two and three case studies, 
respectively with each case study combining only 2–5 microarray datasets) 
were very limited. In addition, some key conclusions from the two papers 
were even contradictory. Therefore practical guidelines for choosing the 
‘best’ meta-analysis method(s) still lack. 
Four meta-analysis methods corresponding to the three most 
common relative meta-analysis approaches (i.e. combining p-values, 
combining effect size and combining ranks) were applied to the selected 
MPM datasets using three R and Bioconductor packages (metaMA, 
GeneMeta and RankProd). In addition the preprocessed data from the 
three studies have been directly combined and analyzed using limma, 
including a study effect in the linear model. This approach can be viewed 
as an alternative meta-analysis method. 
The different methods resulted in significant gene lists of different 
sizes. The highest number of DEGs was detected by the weighted inverse 
normal p-value combination method. This high proportion of significant 
genes may be due to the fact that p-value combination approaches are in 
general prone to be driven by significant results of individual studies. This 
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drawback may be partly reduced by the introduction of study-specific 
weights as demonstrated by Li and Ghosh [164]. On the other hand, effect 
size combination methods were found to be the most conservative. Taking 
into account the between-study heterogeneity, which is particularly 
evident in our data, they lead to a more reliable and perhaps more 
meaningful set of commonly DEGs. The RankProd approach identified an 
intermediate number of DEGs. Although it does not incorporate the 
between-study variability, it has been widely shown that gene rankings 
from the RankProd method are more robust against noise and other 
hidden variables embedded in different datasets [109]. Finally, limma 
analysis including a study effect in the linear model also appeared to be a 
valuable alternative for meta-analysis. 
A poor overlap between the DEGs lists provided by each method was 
observed, both considering the complete lists and the top 500 most 
significant DEGs. The overlap increases when filtered data are considered 
indicating a possible beneficial effect of filtering on our data. The fact that 
a significant number of genes were only detected by one of the methods 
stems from the different assumptions and ranking criteria on which the 
various methods are based. Therefore, when doing meta-analysis on real 
data, it might be useful to select candidate genes using a combination of 
methods, so as to capture genes that are interesting from different 
aspects. In particular, DEGs detected by more than one meta-analysis 
method may be considered as the most reliable ones while DEGs 
identified by only one method may be further explored to enrich the 
knowledge of the biological phenomenon of interest. 
Despite the poor overlap of the results at the gene-level, the pathway 
analysis showed a higher concordance between the different methods, in 
particular when the filtered data were considered.  
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The present meta-analysis and the final DEGs lists may have some 
potential value as regards MPM, since this is the first attempt to integrate 
microarray datasets in this area. However such genes lists should be taken 
with caution due to the limitations of this microarray meta-analysis, first 
of all the small number of studies included. Regarding meta-analysis 
methodology with microarray data, some limitations emerge from this 
work. The fact that several microarray studies share the same hypothesis 
would not be sufficient to successfully integrate results; such studies 
should use the same sample sources (biological equivalency of cases and 
controls across studies), similar sample processing protocols and the same 
microarray platform, with identical probes in the chips. Otherwise, the 
search for genes in common among platforms and the precision of data 
could reduce the power of individual studies instead of increasing it. 
Furthermore, if DEGs do not present large differences among the groups 
compared, the results of the meta-analyses could be strongly affected by 
experimental error and patient variability. Finally, the sensitivity of the 
results from meta-analysis should be tested before a final conclusion is 
reached. We could not perform any sensitivity analysis because of the 
small number of included studies and the lack of suitable packages/tools. 
In fact, the sensitivity analysis has so far been largely neglected in the 
meta-analysis of microarray data.  
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5 CONCLUSIONS 
Despite the increasing popularity of microarray meta-analysis, many 
issues remain unsolved that can hinder the effectiveness of its application. 
Although many methods have been proposed and used in published 
applications, a detailed workflow to perform microarray data meta-
analysis does not exist yet. 
Although many grant agencies and peer-review journals now require 
to make data available, many old studies or new studies funded by private 
foundations are still not publicly accessible. Studies with censored or 
incomplete information can be an obstacle for meta-analysis. 
It is still unclear how measurements from different platforms 
compare with each other and inconsistencies in gene coverage and 
annotation make comparison much more difficult. 
Several microarray meta-analysis methods have been developed. The 
selection of a suitable meta-analysis method depends on the type of 
analysis desired and the hypothesis setting behind each method. 
Ramasamy and colleagues [48] recommend effect size combination 
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methods as the most comprehensive approach for meta-analysis of two-
class gene expression microarrays due to its known advantages However 
there is no consensus on what is(are) the ‘best’ meta-analysis method(s). 
A large-scale comparative study and simulation study with adequate 
evaluation measures are needed to provide insights and practical 
guidelines for choosing the ‘best’ meta-analysis method(s) in practice. 
Only a few of the proposed microarray meta-analysis methods are 
developed in easy to use software packages. In addition to the scarcity of 
software packages in the field and the lack of a regular update of the 
existing ones, most of the available packages either did not have clear 
manuals or had functions that were not easy to apply. Efforts to provide 
high-quality documentation of programs in order to make them more 
reliable and easier to comprehend are well summarized by the concept of 
‘literate programming’ and its implementation developed by Knuth [Knuth 
DE, 1984]. The package Sweave [165] is an example of use of the noweb-
like literate programming tool [166] inside the R language for creation of 
dynamic statistical reports. It provides a flexible framework for mixing text 
and R code for automatic document generation. A single source file 
contains both documentation text and R code, which are then embedded 
into a final document containing the documentation text together with 
the R code and/or the output of the code (e.g. text, graphs, tables) by 
running the code through R. The report can be automatically updated if 
data or analysis change, which allows for truly reproducible research. 
All packages available by Bioconductor now should meet this 
requirement and, in fact, the most recent packages contain one or more 
‘vignettes’, that is documents providing a textual, task-oriented 
description of the package's functionality. Due to its widely recognized 
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benefits, literate programming practice should be promoted in future 
software development. 
Heterogeneities caused by demographic, clinical and technical 
variables often exist within and across studies. Failure to consider these 
potential confounding variables in the statistical models and meta-analysis 
can result in reduced statistical power or false positives. Meta-analyses of 
clinical and epidemiological studies use regression modeling to adjust for 
the confounding effects. Only recently similar techniques have been 
extended to microarray data meta-analysis [167] however further efforts 
are needed in this area. 
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